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ABSTRACT
The C57BL/6J inbred mouse strain has been used extensively to study human alcoholism
because of its well-established tendency to preferentially consume alcohol-containing solutions
over those of pure water. In the current study, this innate preference was exploited to examine the
effects of self-administered ethanol by pregnant dams on the outcomes of offspring as a novel
rodent model for the Fetal Alcohol Spectrum Disorders (FASD) observed in human populations.
Behavioural analyses determined that the acquisition of developmental milestones, spontaneous
and nocturnal activity levels, anxiety, learning and memory were significantly altered in offspring
of mothers who consumed ethanol during the periods of mouse pup neurodevelopment that
correlate with the three trimesters of human pregnancy. Moreover, these behavioural and neuro
developmental changes were associated with the altered expression of several genes considered
important for learning, anxiety, and disorders of central nervous system dysfunction.

Keywords: fetal alcohol spectrum disorder, gene expression, behaviour, mouse model, ethanol
teratogenesis, neurodevelopment
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CHAPTER 1. INTRODUCTION
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1.1 Fetal Alcohol Spectrum Disorders (FASD)
The potential for ethanol to inflict widespread damage on a developing fetus has
been documented in research literature dating back as early as 1968, when French
scientist, Lemoine, and his colleagues first documented a cluster of physical and
behavioural abnormalities common to infants of alcoholic women. In 1973, investigators
Jones and Smith reported a similar constellation of features in this infant population—
namely, growth restriction, mental retardation, and various craniofacial, cardiac, and
skeletal abnormalities, which led them to propose that prenatal alcohol exposure was the
cause of this condition, which they termed Fetal Alcohol Syndrome (FAS) (Jones et al.,
1973). Since this time, researchers have become increasingly aware of the diverse and
deleterious effects that alcohol exposure can inflict on a developing fetus (Clarren et ah,
2001; Burd et ah, 1999; Chudley et ah, 2005) and efforts to understand the mechanisms
underlying both FAS and other fetal alcohol exposure related abnormalities are ongoing.
Rather than being the cause of a single, unique syndrome, as was initially
suggested by Jones and Smith, fetal alcohol exposure is now considered responsible for a
broad range of disabilities, ranging from very mild cognitive and/or behavioural deficits,
to more profound abnormalities that disturb an individual’s morphology, physiology,
cognitive abilities, social and emotional development, and behaviour (Stratton et ah,
1996). In the most visible form of the disease—that now known as full Fetal Alcohol
Syndrome (FAS)—ethanol reveals its highly encompassing capacity for teratogenesis, as
a devastating combination of cranio-facial malformations, growth retardation, mental
retardation, and central nervous system dysfunction (Sampson et ah, 1997; Astley &
Clarren, 1995). This is not to say that the many children who exhibit no obvious physical
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manesfestations of the disease and only present with the cognitive and behavioural
deficits are less adversely affected; rather, the severity of cognitive-behavioural
abnormalities is considered independent of the physical effects, and these children can be
as behaviourally and mentally impaired as those with the distinct physical malformations
(Mattson et al., 1997; Mattson et al., 1998; Mattson et al., 1999). Moreover, these
children are much less likely to receive a proper diagnosis, and thus, less likely to receive
access to resources and intervention efforts (Welch-Carre, 2005).
The adversity faced by individuals with FASD is not limited to infancy. In fact,
these individuals are considered to be at high-risk for a plethora of secondary disabilities
that result as a consequence of the difficulties they incur from their primary disabilities—
or those that they are bom with (Clark et al., 2004). For example, individuals with FASD
are commonly reported to have learning disabilities, problems with vision and audition,
and altered levels of activity—most commonly hyperactivity, but some present with
pronounced hypoactivity—all of which can interfere with their ability to succeed at
school both academically and socially (Astley, 2004; Steinhausen et al., 2003). Moreover,
beginning in adolescence, these individuals display a propensity towards criminal
behaviour, repeated and inappropriate sexual behaviour, addiction and mental illness, and
poor social skills, all of which are problems considered to arise from the inborn cognitivebehavioural deficits accrued from early ethanol exposure (Fast et al., 2009; Streissguth et
al., 1996; Baer et al., 2003; O’Connor et al., 2009; McGee et al., 2008).
1.2 Prevalence and Cost of Fetal Alcohol Spectrum Disorders

4

Despite the fact that FASDs are a completely preventable ailment, prevalence
rates have not substantially declined since the discovery of ethanol as the causative agent.
Although estimates of the frequency of “heavy” drinking during pregnancy vary widely
between studies depending on how it is defined, about 3% of women admit to drinking in
a “binge” fashion and about 10% to drinking in any amount, throughout their pregnancies
(SAMHSA, 2002). Moderate levels of consumption should be considered important for
investigation as well, as even this less extensive prenatal exposure to ethanol is capable of
producing adverse outcomes in children (Coles et al., 1985; Windham et al., 1995;
Simpson et al., 2005).
Estimates of the prevalence of FASDs in North America begin at approximately
l-per-every-1000 individuals, yet are projected to be as high as 1-per-100 individuals in
higher-risk communities (Coles 1993; Quinby and Graham 1993; Chudley et al., 2005;
Sampson et al., 1997). When consideration of all of the medical, social, and legal costs
associated with individuals with FASD is tallied, the annual cost in Canada has been
proposed to be about $5.3 billion dollars (Stade, 2009), with estimates exceeding $14,
000 in the additional costs per year associated with raising a child with FASD (Stade et
al., 2006).
As of right now, there is no cure for FASD, and although early intervention efforts
show modest efficacy in ameliorating some behavioural irregularities (Peadon et al.,
2009), psycho-social therapies may not be enough to appreciably reverse much of the
damage done in utero. Accordingly, scientists are searching for underlying molecular
mechanisms that contribute to the etiology of FASD, in hopes that they may prove a more
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efficacious target for therapeutic measures, or complement existing intervention
strategies.
1.3 Animal Models of FASD
Due to the obvious ethical limitations of performing research with human
subjects, animal models have been the basis for much of the research that has been
executed in search of the mechanisms involved in the development of FASD. A variety of
organisms have been used for this purpose, including mice, rats, guinea pigs, rabbits,
sheep, species of fish, chickens, dogs, pigs, and monkeys (Allan et al., 2003; Sherwin et
al., 1979; Gareri et al., 2009; Schwetz et al., 1978; Gray et al., 2008; Bilotta et al., 2004;
Becker et al., 1998; Ellis and Pick, 1980; Dexter and Tumbleson, 1980; Kraemer et al.,
2008). Unlike human studies, animal research allows for the highly precise quantitation of
ethanol consumption/exposure, exact knowledge of the timing and pattern of exposure, as
well as control over other variables that may influence the fetal environment.
Additionally, the limitations common to retrospective studies and self-reporting are
eliminated. The generally shorter gestational period in animals permits investigations of a
more timely manner, and the relative low cost of animal studies ensures an adequate
sample size of subjects.
Nearly every FASD characteristic seen in humans has been replicated in animal
models of prenatal ethanol exposure, and in particular, rodents show high similarity in
many of the core deficits and deformities common to this population (Adams et al., 1986;
Driscoll et al., 1990). Features that have been replicated include facial dysmorphology
(Sulik, 2005); microcephaly (Diaz & Sampson, 1980) changes in brain size and cell
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number in specific areas (Dikranian et al., 2005; Nathaniel, 1986; Zhou et al., 2001),
growth retardation (Amini et al., 1996; Nathaniel, 1986), heart and skeletal defects
(Driscoll et al., 1990; Serrano et al., 2010; Chemoff, 1977), learning deficits (Reyes et al.,
1989; Savage et al., 2002; Gianoulakis, 1990), normal reflex and motor development
(Gottesfeld et al., 1990; Lopez-Tejero et al., 1986; Ciociola et al., 1988), changes in
activity level (Becker et al., 1989; Wang et al., 2009; Wilcoxon et al., 2005), and visual
(Cook et al., 1987; Sulik et al., 1988; Harris et al., 2000) and auditory (Church, 1987)
system dysfunction.
1.4 C57BL/6J Mouse Strain and FASD
In addition to the practical and economic benefits of performing research with
mice, we have chosen to use the C57BL/6J or C57 mouse strain in our analyses for a
number of distinct reasons. Firstly, the C57s are an inbred, genetically-identical mouse
strain which controls for the phenotypic differences due to diversity in DNA sequence
common to human genetic analyses and can help minimize the litter effects common to
rodent studies. Moreover, the genome of this strain has been fully sequenced and is
accessible online and available for use with a variety of bioinformatics tools (Mouse
Genome Sequencing Consortium). Secondly, the C57’s have a well-understood
neurodevelopment, and one which can be correlated with that of humans to draw the
cross-species comparisons necessary for a useful animal model. Thirdly, this strain has
been shown to display high sensitivity to the teratogenic effects of prenatal ethanol
exposure, and most importantly, in ways that mimic the morphological and behavioural
teratogenesis observed in humans exposed to alcohol prenatally (Downing et al., 2009;
Becker et al., 1996).
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The most critical reason we opted to use the C57 mouse strain for our
investigation is because it has the unique and well-established tendency to prefer
solutions containing 10% ethanol to those of pure water (McCleam and Rodgers, 1959;
Fuller, 1964; Belknap et al., 1993), leading to levels of intake considered biologically
relevant to human consumption (Crabbe et al., 2002; Kaminen-Ahola et al., 2010; Allan
et al., 2003; Caldwell et al., 2008). Daily alcohol preference (AP) measures, taken when
C57s are given access to both 10% ethanol and water tubes allowing choice of fluid
consumption, are generally in the 60-80% range (Bachmanov et al., 1996; Belknap et al.,
1993). This stands in stark contrast to the levels of non alcohol-preferring strains, such as
the DBA/2J (D2) strain, which has an AP of approximately 10% (McCleam and Rodgers,
1959). The C57 strain’s propensity for alcohol consumption has led to its extensive use in
studies seeking to uncover the genetic correlates of alcoholism (Phillips et al., 2010;
Lesscher et al., 2009; Weng et al., 2009; White et al., 2007); however, their penchant for
alcohol intake has rarely been exploited as a means to explore the genetic susceptibility in
FASD. Interestingly, this strain’s attraction to ethanol-containing solutions permits the
use of a novel paradigm for exposing mouse fetuses to alcohol prenatally—the continuous
preference drinking (CPD) paradigm.
1.5 The Continuous Preference Drinking (CPD) Paradigm
In the CPD exposure paradigm, pregnant mice are provided with access to two
drinking tubes, one containing 10% ethanol in tap water, and the other containing only tap
water, throughout the gestational and early post-natal periods. Rodent models of FASD
have also utilized two other types of paradigms to expose fetuses to ethanol. The first is
the injection or “binge”exposure paradigm, in which pregnant mice are injected
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intraperitoneally or subcutaneously on one or several days of gestation, assuring a
formidable level of exposure to ethanol in utero. The second common paradigm is one
involving the forced intake of ethanol in pregnant dams, by providing ethanol-containing
solutions as the only source of fluid to ensure intake. While these paradigms indeed
guarantee significant alcohol exposure to pups prenatally, they are problematic in that
they introduce either injection stress or an often severe dehydration and/or nutritional
stress in the pregnant dams. The CPD paradigm provides a novel technique for exposing
pups to ethanol through their mothers self-administered alcohol intake, which removes
the injection and dietary difficulties of the traditional paradigms.
Variants of the CPD paradigm have, in fact, already been used to study both
alcoholism and FASD in rodents. Investigators have developed ways of introducing
ethanol to rodents in solutions sweetened with sucrose or saccharin to establish regular
patterns of drinking in strains of mice or rats who would not normally consume
significant amounts of ethanol-solutions by choice (Carrillo et al., 2008). These
sweetened ethanol procedures are useful for the initiating alcohol self-administration in
both mice and rats, and thus, one can use them to study the effects of consumption on the
physiology of the animal and/or of their subsequent offspring. However, sweetened
solutions can significantly alter the blood alcohol levels (BAL) attained by rodents,
(Roberts et al., 1999; Matthews et al., 2001) such that the resulting BALs are much lower
in combined sucrose and ethanol consumption. Considering that most animal research
supports the notion that BAL is the most significant predictor in determining severity of
outcome (Driscoll et al., 1990; Jacobson et al., 1998; Pierce and West, 1986), using
sucrose may not be optimal for studies of FASD if it interferes with the ability of self
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administration to generate biologically relevant levels of ethanol in the bloodstream.
Again, the advantage of the C57 strain is echoed here because they have no need for an
additive to the ethanol solution, and will drink ethanol in water alone.
1.6 Phenotypic Variability in FASD
One of the current objectives in FASD research is to understand the reasons for
the marked phenotypic heterogeneity amongst individuals living with this condition in
hopes that it may help to elucidate the varied and complex molecular mechanisms
influencing the development of these disorders.
1.6.1 Environmental Sources of Variation
Although it is now widely accepted that ethanol is capable of producing adverse
and life-lasting effects on a developing fetus, the reason for the marked variability in
phenotypic outcome between different individuals exposed to alcohol prenatally is much
less well-understood. A significant portion of this variability has been attributed to
differences in the timing of ethanol exposure to the fetus—as particular anatomical
structures reach peak vulnerability to ethanol teratogenesis at different periods of fetal
development, based upon their own developmental ontogeny (Rice et al., 2000; Goodlett
et al., 1996). The period of maximal sensitivity to teratogens takes place during the first
trimester for the heart, upper and lower limbs, eyes, ears, palate, teeth and external
genitalia, although damage can still occur to many of these structures in the 2nd and 3rd
trimesters (Moore & Persaud, 1993). This temporal sensitivity is reflected in the gross
morphological changes, including cranio-facial malformations and severe organ
abnormalities that are more commonly reported after cases of exposure to ethanol in the

10

earlier stages of pregnancy (Cook et al., 1987; Rana, 1998; Sulik, 2005; Windham et al.,
1995; West et ah, 2005). In contrast, exposure during later stages of pregnancy, when
many areas of the brain continue to experience significant periods of growth and
differentiation, often result in cognitive and neuro-behavioural deficits that are
unaccompanied by any obvious physical effects, although this is not without exception
(Driscoll et ah, 1990; Tran et ah, 2000).
Differences in the dosage of ethanol have also been explored as a potential factor
underlying the variability in FASD, with most studies supporting the notion that peak
BAL is the most powerful predictor of disability in offspring (Driscoll et ah, 1990;
Jacobson et ah, 1998; Pierce and West, 1986). The fact that a single binge exposure
produces more detrimental outcomes than an extended exposure that is equivalent in
alcohol quantity is attributed to the fact that the high-BAL peaks produced in the former
exposure style are not attained in the latter (Olsen et ah, 1997; Pierce and West, 1986;
Bonthius et ah, 1988). For this reason, much of the animal research on FASD has focused
on the effects of episodic or “acute” binge-levels of ethanol exposure, leaving less known
about the impact of a more moderate, but chronic, exposure regimen.
1.6.2 Genetic Sources of Variation
In 1993, Streissguth and Dehaene published a report of a twin study they had
conducted with 16 pairs of twins; 11 of whom were dizygotic, 5 of whom were
monozygotic, and all of whom had been heavily exposed to alcohol prenatally. The
researchers reported that all 5 of the monozygotic twin pairs were concordant in their
diagnosis of FAS/FAE/no diagnosis, whereas 7 of the dizygotic twin pairs were
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discordant in their diagnosis (Streissguth and Dehaene, 1993). These findings, in tandem
with other reports of discordance in FASD diagnosis amongst dizygotic twin pairs
(Christoffel and Salafsky, 1975) prompted investigators to question if and how genetic
factors may confer differential vulnerability to the teratogenic effects of ethanol in útero.
Work comparing the responsivity of different strains of mice to ethanol in útero
has also supported the notion that genetic influences may predispose some portion of
vulnerability, as different strains have exhibited varying degrees of susceptibility to
ethanol teratogenesis (Becker et al., 1996; Downing et al., 2009). The identification and
examination of susceptible and resistant strains of mice can help provide information
regarding the molecular mechanisms that underlie the development of FASD, through the
elucidation of the impact of genetic contributors in the disorder. For example, Gemma et
al., (2007) found that the differential activity of alcohol dehydrogenase (ADH) in 3
different mouse strains was strongly related to the BAL achieved as well as the severity
of teratogenesis in the offspring. This activity is considered likely to be regulated at the
genetic level (Chemoff, 1980), and thus, may represent a genetically-based vulnerability
to the harmful effects of prenatal ethanol exposure.
Polymorphisms Associated with FASD Vulnerability
Most commonly, gene studies have looked at the relationship between different
alleles of a particular gene and the risk of FASD phenotypes. Of particular interest have
been polymorphisms in genes known to code for enzymes involved in alcohol
metabolism, as these enzymes’ activity is strongly related to the blood alcohol level
attained in an organism (Chemoff, 1980). For instance, the alcohol dehydrogenase
(ADH), aldehyde dehydrogenases (ALDH1, ALDH2), and cytochrome P450 2E1
(CYP2E1) genes have been studied to determine whether they may confer differential
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vulnerability to ethanol teratogenesis because of their involvement in the metabolism of
ethanol (Hayashi et al., 1991). Results have been mixed, although it does appear that
polymorphisms in the ADH1B gene are associated with the risk for FASD, with a
maternal ADH1B*3 allele displaying a protective influence on the adverse effects in the
fetus (Jacobson et al., 2006; Warren and Li, 2005).
Various other genes, thought to play important roles in neurological development
or behaviour, have been selected to examine their association with FASDs. The serotonin
transporter gene promoter (5-HTT) has frequently been studied, because through its
involvement with the serotonin neurotransmitter system it is implicated in early brain
organization and may be involved in many maladaptive behaviours seen in humans
(Sodhi et al., 2004; Nordquist et al., 2010). Researcher Schneider and colleagues (2009)
examined the impact of the 5-HTT polymorphism on fetal alcohol exposure-related stress
reactivity. Both infants and rodents exposed to alcohol prenatally are known to display
hypothalamic-pituitary adrenal (HPA) axis dysrégulation as well as heightened
susceptibility to anxiety disorders (Lee et al., 2000; Hellemans et al., 2008; Haley et al.,
2006). This study found that rhesus monkeys, who had been prenatally exposed to
ethanol, displayed increased irritability and stress-reactivity if they carried a copy of the
“short” allele of the 5-HTT gene when compared to ethanol-exposed monkeys who
carried two copies of the “long” allele, or to control monkeys who had not been exposed
to ethanol (Schneider et al., 2009). These results indicate that prenatal ethanol exposure
and genotype can interact considerably to produce FASD-relevant phenotypes; in this
case, a tendency towards anxiety-related behaviours. Moreover, this study is illustrative
of the “diathesis-stress model” conceptualization of mental disorders, with alcohol
providing a significant prenatal stressor inducing elevated rates of mental disease in
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offspring with a pre-existing diathesis—the short form of the 5-HTT allele.
1.7 Ethanol-Responsive Genes
Another approach to studying the genetic mechanisms that underlie FASD is to
examine the genes that are responsive to prenatal ethanol exposure, indicated by an up- or
down-regulation of their expression in a particular tissue. Several ethanol-related changes
in gene expression have been reported for loci known to be involved in FASD-relevant
abnormalities, and thus, may be involved in producing the phenotypic effects observed in
the disorder. Ahlgren and colleagues (2002) found that administration of ethanol to chicks
(Gallus gallus domesticus) in utero led to drastic down-regulation of sonic hedgehog
(shh) mRNA in the embryonic neural crest cells—precursors of the cranio-facial cartilage
and bones. Shh is a protein considered essential for cranio-facial development, and shhmutations are related to severe brain and facial abnormalities in both human and rodents
(Chiang et al., 1996; Roessler et al., 1996). The researchers found that application of shh
protein to ethanol-treated chick embryos was capable of blocking the cranio-facial
deformities, and thus, the shh-signalling pathway may prove a potential therapeutic target
for victims of human FASD.
Another gene that is considered crucial for the normal embryonic development of
the facial and cranial structures, including the eyes and ears, is the homeobox gene msx2
(Hill et al., 1989; MacKenzie et al., 1991). This gene is a regulator of these
developmental processes and was explored as a potential mechanism for ethanol-related
cranio-facial dysmophism in a rodent model of FASD by Rifas and colleagues (1997).
These investigators found that after exposure to ethanol on gestational day 8 there was no
detectable msx2 expression in the embryos on gestational day 11, whereas msx2
expression was evident in a plethora of structures in untreated embryos on the same
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gestational day (Rifas et al., 1997). This study, in tandem with in vitro findings of msx2
promoter-specific suppression in osteoblastic cells of the embryonic mouse skull (Rifas et
al., 1997), suggests that fetal alcohol exposure decreases msx2 expression and thus, may
contribute to the characteristic growth retardation and cranio-facial dysmorphogenesis
observed in FASDs.
In addition to genes implicated in the structural and physical abnormalities of
FASD, there are also genes that have been altered due to fetal alcohol exposure that may
provide information regarding the underlying mechanisms of behavioural dysfunction.
Toso and colleages (2006) investigated the impact of acute prenatal ethanol exposure on
gestational day 8 (through injection) on the expression of genes in the perinatal brain on
gestational day 18. The investigators found that the expression of GABA(A)alpha5 was
dysregulated in prenatally ethanol-treated mice in both the total embryo sample as well as
specifically, the embryonic brain, expression was significantly decreased, yet in adult
mice, there was a significant upregulation of the gene. This receptor has been implicated
in learning (Freund and Buzsaki, 1996) and Toso et al. (2006) confirmed previous
findings that prenatally alcohol-exposed mice, and in fact, the litter-mates of those used
for gene-expression analysis, had learning deficits in adulthood. These findings support
the notion that alcohol-mediated alterations in central nervous system structure and
functioning may underlie the learning and memory impairments in individuals with
FASD.
1.8 Ethanol as a Teratogen
It has long been known that alcohol is capable of crossing the placenta and
entering fetal circulation (Nicloux, 1899). However, the ability of ethanol to interfere
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with normal fetal development was something not recognized until much later—resulting
in its classification as a teratogenic agent (Jones et al., 1973; Sulik et al., 1983; Obe et al.,
1979). Ethanol is considered a “classic” teratogen and its capacity to induce a wide range
of defects during the prenatal period has been well documented, despite the fact that the
underlying molecular mechanisms involved in producing these abnormalities are much
less well understood. Anomalies from fetal alcohol exposure can be seen in numerous
brain regions including the hippocampus (Fukui et al., 2009; Livy et al., 2003; Klintsova
et al., 2007), cerebellum (Jaatinen et al., 2008; Dikranian et al., 2005), basal ganglia
(Mattson et al., 1996), frontal lobes (Astley et al., 2009), and corpus callosum (Ma et al.,
2005; Wozniak et al., 2006). As these commonly affected areas are implicated in a wide
variety of cognitive and behavioural functions, it is not surprising that the deficits
observed in FASD are so encompassing and have led to the additional recognition of
ethanol as a behavioural teratogen (Streissguth et al. 1986).
One way in which ethanol has been postulated to directly effect fetal development
is by increasing neuronal cell death through various mechanisms including the induction
of apoptosis, increasing oxidative stress, excitotoxicity, as well as through its toxic
metabolite, acetaldehyde (Henderson et al., 1995; Onley et al., 2002; Smith, 1997;
Thomas et al., 1997; Yelin et al., 2005; Eriksson, 2001). There is additional evidence that
ethanol may inhibit the synthesis of proteins and DNA, resulting in fewer cells and
decreases in their growth and differentiation (Gallo et al., 1986; Barr et al., 2005;
Halmesmaki et al., 1986). There are also various secondary, more indirect ways that
ethanol can influence fetal development, including contribution to nutritional deficits,
interference with growth factors and cell-signalling mechanisms, and causing changes in
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circulation and placental morphology (Carey et al., 2003; Jones et al., 1981; Yelin et al.,
2005; Seyoum et al., 1995).
These processes are not considered to be trivial in their consequences and are
likely contributors to the observed physical and functional abnormalities seen in FASD.
In fact, in animal models the simultaneous application of many molecules, including
neurotrophic factors, proteins involved in cell migration and differentiation, exogenous
vitamin supplementation, and anti-oxidants, is able to reverse many of the FASD-related
defects in ethanol-treated offspring (Incerti et al., 2010; Spong et al., 2001; Wilkemeyer
et al., 2002; Siler-Marsiglio et al., 2004; Endres et al., 2005; Henderson et al., 1995;
Heaton et al., 2006; Wentzel et al., 2006). These findings lend support to the suggestion
that these mechanisms are integral in the production of alcohol’s teratogenic effects.
Evidence is beginning to accumulate that one additional mechanism, by which
ethanol may exert its deleterious effects, is interference with epigenetic programming of
the genome. Epigenetic mechanisms control the spatial and temporal expression of genes
during development, and disruptions of these processes may account for changes in gene
expression that are observed in offspring exposed to ethanol prenatally (Bonsch et al.,
2006; Haycock, 2009). Ethanol has been shown to interfere with various mechanisms
required for the regulation of gene expression, including one-carbon metabolism, DNA
methyltransferase activity, histone modifications, and small noncoding RNAs (Trimble et
al., 1993; Bielawski et al., 2002; Garro et al., 1991; Kim and Shukla, 2006; Shukla et al.,
2008; Liu et al., 2009; Pietrzykowski et al., 2008; Sathyan et al., 2007; Wang et al.,
2009). Moreover, aberrant methylation following prenatal alcohol exposure has been
found to correlate with the prevalence of defects in the fetal neural tube (Liu et al., 2009).
Although studies of epigenetic mechanisms are just emerging in FASD research, the
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preliminary findings suggest that they may play an important role in the etiology of many
FASD-related abnormalities and are worthy of further investigation.
1.9 Strategies for Identifying Genes and Biochemical Pathways affected by Fetal
Alcohol Exposure
1.9.1 Candidate Gene Analyses
The candidate gene approach is one method for identifying genes that may
contribute to FASD phenotypes. This approach involves assessing the association of the
disorder with variation in a particular gene—selected for analyses because of its known
function and anticipated role in the phenotype of interest. Across individuals, different
alleles of the candidate gene, or variation in levels of expression of that gene at a
particular time point, can be compared to determine their associated risk for the disease.
The aforementioned dehydrogenase enzymes, for example, have been extensively
examined to assess whether different polymorphisms in ADH or ALDH were related to
FASD vulnerability in various populations (Warren and Li, 2005). Other studies have
examined whether changes in the expression patterns of specific genes of interest are
observed following prenatal ethanol exposure, indicating ethanol-sensitivity and a
possible role in FASD phenotypes (Toso et al., 2006).
The candidate gene approach is considered useful for rapid detection of the
association between a genetic variant and a phenotype of interest. However, many more
genes than those expected, based on functionality, can be involved with a disease. Thus,
this approach may only provide a single and rather narrow view of the underlying
mechanisms.
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1.9.2 Gene Expression Studies
A second approach to identifying genes that may underlie FASD phenotypes is a
genome-wide, gene expression analysis. This is a hypothesis-free method where no a
priori predictions are made regarding the likely involvement of particular genes. Instead,
the data are examined to determine the relevant genes based upon their differential
expression after prenatal ethanol exposure. A microarray analysis is one method of
genome-wide investigation and, although it is less sensitive for precise quantitation than
other techniques such as real time reverse transcriptase polymerase chain reaction (RTPCR), it has the benefit of permitting thousands of genes to be examined at the same time
(Genter et al., 2003). Arrays allow the investigator to observe global patterns of gene
expression changes and allow identification of groups of related genes that respond to
prenatal ethanol exposure. They also may provide novel insights into relationships
between these genes and the phenotypes of interest (Rahman and Miles, 2001).
Expression profiling can provide a starting point and an indication of which genes may be
important for further confirmation and analysis by the more traditional and highly
sensitive methods such as RT-PCR.

1.10 Pathway Analyses
One of the main challenges of interpreting gene expression data is the sheer
volume of results generated by the microarray. Various online tools have been developed
to deal with this abundance of information, allowing the data to be input to a program
which can highlight the biologically-relevant pathways, interactions, functions, and
diseases that involve the genes of interest. The Pathway Express Console (Intelligent
Systems and Bioinformatics Laboratory, Detroit, MI) is considered the best pathway
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analysis system to date, providing the investigator not only with the biological pathways
implicated by the genes, but also with statistical information regarding the likelihood that
the number of genes observed in this pathway would be found dysregulated together by
chance alone (Draghici et al., 2007).
The Pathway Express Console calculates various variables from information
derived from the differentially expressed gene lists. The first is a perturbation factor (PF)
for each of the genes input into the program, and reflects the relative importance of each
differentially expressed gene implicated. The PF considers the fold-change of each gene
as well as the number and fold-changes of dysregulated genes that are downstream from
it.
Using the perturbation factor, an impact factor (IF) is then calculated for each
pathway implicated by the differentially regulated genes, which additionally considers the
proportion of dysregulated genes in that pathway. The IF is used to rank the pathways,
with the largest impact factors ranked highest (Khatri et al., 2005).
Pathway analyses are useful for genome-wide studies because they simplify and
reorganize the data to identify relevant focal points, which can help investigators generate
and explore hypotheses about if and how various biological pathways are involved in
generating the phenotypes of interest.
1.11 Hypotheses of the Present Study
Hypothesis 1. Pregnant C57 females will choose to consume levels of 10%
ethanol solution on a daily basis throughout gestation and the early post-natal period
(considered equivalent to the third trimester in humans) comparable to the levels of non
pregnant C57 females.
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Hypothesis 2. Continuous Preference Drinking (CPD) by pregnant C57 mice will
expose fetuses and subsequently neonates, to sufficient levels of ethanol to induce FASDrelevant deficits in development, activity levels, anxiety, learning and memory in the
resulting offspring.
Hypothesis 3. Changes in offspring development and behaviour will be related to
changes in the level of expression of genes considered functionally-relevant in these
phenotypes, due to ethanol exposure at critical time periods.
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CHAPTER 2. MATERIALS AND METHODS
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2.1 Mouse Strain and Care Procedures
All usage of mice required by this research procedure was approved by the
Animal Use Subcommittee (AUS) at the University of Western Ontario, London, Ontario,
Canada (see appendix A). Originally, mice of the C57BL/6J (C57) strain were obtained
from the Jackson Laboratory (Bar Harbor, ME) and later, an in-house population was
maintained at the Animal Care and Veterinary Services Facility in the Medical Sciences
Building at the University of Western Ontario. In the mouse facility, mice were housed in
standard 7” by 11” shoebox cages containing woodchips (Beta Chip, NEPCO,
Warrensburg, NY) as well as square cotton nestlets which are optimal for bedding
(Ancare, NES 3600, Bellmore, NY). Environmental conditions were maintained at a
14/10-hour light/dark cycle, humidity range of 40%-60%, and a temperature range of 1922°C. Mice were given ad libitum access to water and Lab-Diet® 5P00 ProLab® RMH
3000 (St. Louis, MO). When pups reached 21 days, they were weaned from their mothers
and placed into gender-specific cages of maximum 4 mice per cage, until required for
experimental procedures.
For the purposes of the present experiment, 25 females from the C57 mouse
strain, aged 8 weeks were individually caged for two weeks prior to the overnight mating
procedure, in which they were mated with C57 males aged 8-12 weeks.
2.2 Ethanol Consumption
Mice who were randomly assigned to the treatment group were introduced to
ethanol in a step-wise fashion with increasing concentrations of 2%, 5%, and 10% v/v in
tap water over the 2 week period preceding mating. Concentrations were increased after a
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48 hour period of free-access to the previous concentration—a procedure which has been
shown to optimize consumption levels in the C57 mouse strain (Allan et al., 2003).
Measures of 10% alcohol consumption were evaluated using a two-bottle choice
paradigm, in which both pure water and the ethanol solution are provided ad libitum and
daily levels of consumption of each are measured (Bachemanov et al., 1996). The two
drinking tubes were constructed by Ph.D. student, Julia Weng, according to Bachmanov
et al. (1996). The tubes consisted of 25 ml plastic serological pipettes (VWR, West
Chester, PA) which were fitted with 2.5-inch stainless steel sipper tubes (Girton
Manufacturing, Millville, PA) inside a 0.3-inch diameter of silicone tubing. Rubber
stoppers of size 00 (VWR International, Mississauga, ON, Canada) were utilized to
secure the open end of the tubes and prevent leakage, as well as to provide a vacuum seal.
The positions of the drinking tubes were switched every second day to control for a
potential position preference. During the 2-week ethanol introduction, baseline levels of
ethanol consumption were established for each female, and non- or low-consuming mice,
defined as those consuming less than 2ml of ethanol solution per day, were excluded from
the study. Females were also weighed every second day during this and all subsequent
portions of the investigation.
2.3 Mating
After the two-week isolation period, all females were weighed and then mated
over a 24-hour period with males aged 8-12 weeks. On the day of mating, males were
placed into females’ cages at 9:00 a.m., and were removed at 9:00 a.m. the following day.
During the 24-hour mating, only water was provided to both treatment and control group
females to prevent the cohabiting males from consuming ethanol. Following removal of
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males, females were examined for the presence of a vaginal plug—an indication that
copulation had occurred. The day of the males’ removal was considered gestational day 0.
2.4 Gestation and Post-natal Period
The gestational period of all pregnant dams lasted between 19 and 21 days, and
after parturition on post-natal day 0 (PND 0), pups were allowed to remain with their
mothers until weaning on post-natal day 21 (PND 21). The period that is considered
neurodevelopmentally equivalent to the human third trimester occurs post-natally in mice
and rats, and corresponds to post-natal days 0 to 11-13 (Dobbing & Sands, 1979; Romijn
et al., 1991). Ethanol was removed from dams on post-natal day 10 (PND 10) allowing
the 24-hours required for metabolism and elimination from the body, such that ethanol
exposure was terminated at a point considered neurodevelopmentally consistent with that
of newborn infants. The selection of a suitable exposure period was guided by our
intention to mimic the exposure endured by human infants bom to mothers who
consumed alcohol throughout pregnancy. Because the third trimester equivalent occurs
postnally in mice (Dobbing & Sands, 1979; West, 1987), pups continued to receive
exposure to ethanol throughout this period, but here, via their mother’s milk. Throughout
gestation, the daily intake of both available solutions was measured for treatmentassigned mothers; as well, measurements of weight were taken from both groups of dams
every second day to reduce handling stress.
2.5 Maternal Care Behaviours
On post-natal days 2 and 5, control and ethanol-consuming mothers were tested
for a 15-minute period to assess their maternal care behaviours according to tests
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described for inbred mouse strains in Champagne et al. (2007). Maternal care behaviours
are considered to be a strongly genetically-determined trait, with variations in maternal
responsivity being highly strain-dependent (Ressler, 1963; Carlier et al., 1982). In order
to compare maternal care across treatment groups, mothers were removed briefly from
their cages and 3 pups were taken from their nests and placed randomly about the cages,
and portions of the nests were dispersed throughout the cage. The latencies for mothers to
retrieve each of the 3 pups to the nest, rebuild the damaged nest, begin to lick/groom
pups, and assume the crouching posture over pups (an indication of nursing) were
measured.
In addition, from post-natal day 2 until post-natal day 6, pups were examined for
the presence of milk within their stomachs, which appears through their thin skin as a
white fluid in the stomach, as an indication that they were receiving proper nursing from
their mothers.
2.6 Developmental Milestone Assessment
From post-natal days 2-21 mice were assessed for the acquisition of various
developmental milestones, based upon a protocol designed to measure deviations from
the typical neurodevelopment of the C57BL/6J mouse strain. The age (in days) of pups on
the second consecutive day that they were able to display a positive response, i.e. fulfill
the requirements for the particular “developmental sign, reflex, or coordinated
movement” in question, was recorded (Hill et al., 2007). A total of 30 ethanol-exposed
and 35 control pups were tested, with each daily testing lasting between 2-6 minutes per
pup. Testing commenced at 10:00 a.m. each day, with the dam placed in a separate cage
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throughout the testing procedures, as this appeared to reduce maternal stress. On the first
day of testing (PND 2), a non-toxic black or blue marker was used to label each pup’s tail
by number, so that they were easily identifiable on the following testing days.
Developmental Milestone Tests
a) Weight and Total Length
Beginning on post-natal day 2, the weight and crown to tail-end length of mouse
pups were measured daily.
b) Surface Righting Reflex
Beginning on post-natal day 2, the pup’s ability to right itself on a plastic surface
was evaluated. Pups were gently placed on their backs with all four limbs held to the
ground and once released, the time taken to roll over and place all four paws on the
surface was measured. This test is taken to be a measure of the development of vestibular
function and motor coordination. Positive responses were noted when pups were able to
complete the task in 1 second for 2 consecutive testing days.
c) Negative Geotaxis
Beginning on post-natal day 2 the pup’s ability to rotate its body 180° while on a
sloped platform was tested. Pups were placed on a mesh wire platform, angled at 45° from
the horizontal, with nose pointed towards the ground. The latency to rotate the body so
that the nose pointed upwards was measured and was considered an indication of the
presence of vestibular and postural reflexes. Positive responses were noted when pups
were able to complete the task in 30 seconds or less for 2 consecutive days of testing.
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d) Cliff Aversion
Beginning on post-natal day 2 pup’s ability to avert a cliff was assessed. Pups
were placed with their nose and fore-digits on the end of a 5 cm high platform, and the
latency to back away from the edge, turn, and crawl away was measured. This test is
considered an evaluation of sensory and motor coordination skill development. Positive
responses were noted when pups were able to complete the task within 30 seconds for 2
consecutive days. Falling off the cliff more than once was considered a negative response.
e) Forelimb Grasp
On post-natal day 4 the pup’s ability to grasp a wire rod and suspend its own
bodyweight was evaluated. Pups were placed with their forepaws on a rod held several
inches above a 5-cm deep pile of woodchip bedding. Once released, the time the pup was
able to remain on the rod is measured, with a minimum score of 1 second indicating a
positive response if performed for 2 consecutive days. The presence of adequate balance,
coordination, and motoric strength are assessed by this task (Endres, 2005).
f) Auditory Startle
Commencing on post-natal day 7, pups were tested for the presence of an auditory
reflex in response to a loud noise. This reflex was assessed in the form of a rapid
involuntary jump when the investigator clapped her hands from a distance of 10 cm from
the pup, for 2 consecutive days of testing.
g) Ear Twitch
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On post-natal day 7 the pups were tested for the presence of a tactile reflex of the
ear. The edge of a fine filament was gently rubbed against the pup’s ear 3 times and a
positive response was indicated when the ear twitched rapidly in response to the brushing
motion on 2 consecutive days.
h) Open Field Traversal
On post-natal day 8, pups’ locomotion and ability to extinguish innate pivoting
behaviour was assessed. Pups were placed in the centre of a circle that was 13 cm in
diameter, and the latency to exit the circle—determined by the presence of all four paws
outside of the circle perimeter—was assessed. The first time the exit was made in less
than 30 seconds and later, in less than 15 seconds, for 2 consecutive days was noted as a
positive response.
i) Air Righting Reflex
On post-natal day 8 pups were tested for the presence of vestibular reflex function
and motor coordination in the air righting task. Pups were held upside down about 10 cm
above a 5 cm deep pile of woodchip bedding, and released. Positive responses were
noted when pups righted their bodies such that they landed on all four paws when they
reached the bedding on 2 consecutive testing days.
j) Eye Opening
Beginning on post-natal day 10 pups were examined daily to see whether either
eye was open. The first day in which both eyes were open was considered achievement of
this milestone.
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2.7 Behavioural Testing Battery
a) Open Field Test of Spontaneous Locomotor Activity
At 25 days of age, offspring were introduced to the Panlab Infrared (IR) Actimeter
(Holliston, MA, USA) in which they were each placed alone for a period of 15 minutes.
The apparatus consists of a 450 (W) mm X 450 (D) mm square arena with 450 (H) mm X
350 (W) mm acrylic walls mounted to the base and 16x16 infrared beam sensors around
the perimeter for movement detection. The test was utilized for measuring the locomotor
response of mice to a novel environment by recording interruptions of the infrared beams,
(beam breaks). Measures of total distance travelled; maximum, minimum and average
speed; percentage of time spent resting (moving at 0-2cm/sec), moving slowly (25cm/sec) or moving quickly (>5cm/sec); time spent in each of 10 user-defined zones of
the arena; and the number of rearing responses were recorded with the Actitrack software
(PanLab, Holliston, MA, USA). Testing began at 10:30 a.m. and the field and walls of the
apparatus were wiped down after each test with 30% isopropyl alcohol to remove
olfactory cues.
b) Home Cage Test of Nocturnal Activity
On post-natal day 35, mice were again brought to the Panlab Infrared (IR)
Actimeter in which they were each tested for a period of 12 hours. The period of
recording consisted of the 10 hour dark-period of the mouse light-dark cycle, as well as 1
hour of the light-period just prior to and following it. Subjects were placed in the
transparent plastic testing cage, which included their standard woodchip bedding, food
pellets and water. Mice were introduced to the testing cages at least 24 hours prior to
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commencing testing, so that they could habituate to this new cage environment before the
recording period began. Again utilizing the 16 X 16 IR beams, measures of total distance
travelled; maximum, minimum and average speed; percentage of time spent resting,
moving slowly or moving quickly; and the number of rearings were determined by the
Actitrack software. Data from the analysis software were analysed as a whole (one 12hour period) as well as in blocks (twelve 1-hour periods).
c) Elevated Plus Maze
A subset of mice (control, females = 6, males = 7; treatment, females = 9, males =
8) were introduced to the elevated plus maze as a measure of anxiety-related behaviour.
The maze consists of 4 arms, 2 open and 2 enclosed with walls along them, connected in
a plus-formation such that the mice were able to cross between arms at their discretion.
This maze utilizes rodents’ natural tendencies to seek dark sheltered areas and avoid areas
that are bright and exposed as well as displaying thigmotaxis. (National Research
Council, 1996). At the beginning of the trial, mice were placed facing an open arm at the
intersection of the arms, and their movement/exploratory behaviour was recorded
simultaneously by video-tracking software as well as an observer. The testing was
conducted for a single 5 minute session for each mouse, an interval which is considered
capable of revealing differences in anxiety levels (Waif et al., 2007). The apparatus is
wiped down with 30% isopropyl alcohol following each test to eliminate olfactory cues.
d) Barnes Maze
The Bames Maze was utilized as a test of spatial learning and short- and long
term reference memory in mice aged 50-65 days. The maze was constructed by Ph.D.
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student, Morgan Kleiber, according to Sunyer et al. (2007). The apparatus is comprised of
a circular platform with a diameter of 92 cm, and contains 20 holes (5 cm in diameter) at
equally spaced intervals along the border of the platform (7.5 cm between holes). The
platform is elevated 105 cm above the ground, and is painted white such that it contrasts
easily with the black colour of the C57 mice to optimize tracking by the computer
software. One of the 20 holes along the perimeter is an escape hole through which the
mouse is able to crawl into a dark recessed box, constructed from a Tupperware®
container painted black. A small mesh ramp is placed beneath the target hole to allow the
mouse to easily reach the target box. In addition to the visual cues endogenous to the
testing room, experimenter-prepared visual cues of various shapes and colours were
constructed and placed around the room to provide spatial information about the location
of the target hole. A bright light (150W) was shone from directly above the maze to
create aversive stimuli as well as an 85 dB white noise generated from the Anymaze
Video Tracking software (San Diego Instruments, San Diego, CA).
At the beginning of each acquisition trial, which occurred on testing days 1
through 4, a mouse was placed in the centre of the maze inside a cylindrical start chamber
which was constructed from a tin can painted black. When the start chamber was
removed, the mouse was given a 3-minute trial in which it was permitted to explore the
maze and locate the target hole. If the mouse found and entered the target hole within the
3-minute period, it was rewarded by entry into the dark and secluded target box as well as
with the termination of the white noise, which was turned off by the investigator. If the
mouse did not find the escape hole within the 3 minute period, it was gently guided to the
target at the end of the trial, and allowed to remain inside the target box for a period of 2
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minutes. Mice that found the target hole before the end of the 3 minute trial were also
permitted a 2 minute period of inside of the chamber. Mice were trained on the Bames
maze for four consecutive days, with each training day consisting of four 3-minute trials,
with a 15-minute inter-trial interval. After each trial, the mouse was returned to its home
cage and the maze, target hole, and target box were all wiped down with a 30% isopropyl
alcohol solution. On training days, the latency to find and enter the target hole, as well as
the average speed (in m/sec) and distance travelled were determined by the Anymaze
software. Manual assessment of search strategy was conducted upon analysis of the
videos.
Probe trials were conducted on day 5 and 12 of testing. The target hole was
covered such that it was identical to the other holes on the maze. Mice were again placed
inside the start chamber and then released into the maze whilst being subjected to bright
light and white noise for a single period of 1 minute. On probe days, the latency, average
speed, and path-length to find the former position of the target hole were calculated by the
Anymaze software. The number of errors (incorrect head-pokes) was assessed visually by
examining the videotapes.
2.8 Brain Dissections
Both new control and ethanol-treated litters, as well as older mice that had been
given the behavioural battery of tests were used for whole-brain gene expression analysis.
On post-natal day 14 (PND 14) or 70 (PND 70) male mice were sacrificed at 9:00 a.m. by
C02 asphyxiation and cervical dislocation, and whole brains were removed and washed
with phosphate-buffered saline (PBS) (1.7 mM NathPO-i, 8 mM Na2HP04, 145 rnM
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NaCl). Brains were then flash frozen in liquid nitrogen and stored at -80°C until required
for RNA isolations.
2.9 RNA Isolation and Purification
Total RNA was extracted from PND 14 pups and PND 70 mice using TRIzol®
reagent (Invitrogen, Carlsbad, CA), according to the protocol specified by the suppliers.
One mL of TRIzol® reagent per 100 mg of tissue was used for homogenization of brains
using hand-held glass homogenizers that had been baked to remove RNases and other
contaminants. The homogenate was then transferred into DECP-treated 1.5 mL
Eppendorf tubes (Axygen, Inc., Union City, CA), with each tube containing
approximately 1 mL of homogenate. The samples were then left to incubate at room
temperature for a period of 5 minutes, following which, 0.2 mL of chloroform per 1 mL
of TRIzol® reagent was added to the mixture and vigorously shaken for 15 seconds. The
samples were again left to incubate at room temperature for a period of 2-3 minutes
before being spun at 11 400 rpm for 15 minutes at 4°C in the Sorvall® Microcentrifuge
12V (Sorvall, Newton, CT) to separate the mixture by phase. The resultant aqueous
phase, containing the RNA, was then micro-pipetted into fresh sterile 1.5 mL Eppendorf
tubes. Isopropanol was then combined with the aqueous phase, with 0.5 mL per 1 mL of
TRIzol® reagent being added. The tubes were inverted several times to encourage proper
mixing and left to incubate at room temperature for 10 minutes before being spun a
second time at 11 400 rpm for 10 minutes at 4°C to precipitate the RNA pellet. After
centrifugation, the supernatant was decanted and the pellet was washed with 1 mL of 75%
ethanol per 1 mL TRIzol® reagent. The tube was vortexed to help loosen the pellet from
the inner surface of the tube, and again spun in the centrifuge at 9 000 rpm for 5 minutes
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at 4°C. When the final spin was completed, the 75% ethanol was decanted and the tube
was drained upside-down on a paper towel for 15 minutes to thoroughly dry the pellet.
The RNA was then dissolved in 100 pL of RNAase-ffee water by gentle vortexing and
stored at -80°C until further needed.
2.10 RNA Qualitative and Quantitative Assessment
All RNA quantity and quality assurance tests were performed at the London
Regional Genomics Centre (LRGC), University of Western Ontario, London, Ontario,
Canada. To preliminarily assess the quality of the isolated RNA, 1 pi was micro-pipetted
into the NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific Inc.,
Wilmington, DE), and the corresponding software output values of the concentration of
nucleic acid. As well, the purity of the sample was represented in the form of 260/280 and
260/230 ratios, each of which when significantly lower than 2.00, may indicate the
presence of protein, phenol, or other contaminants that absorb at 280 or 230 nm. A
minimum of 1.80 for both ratios was required before performing further analyses.
Next, to check for the occurrence of RNA degradation, 2 pi of sample was
analyzed by the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Palo Alto, CA)
electropherogram which produced information regarding the integrity of the RNA as
determined by the proportion of fragments of different sizes in the sample. Eukaryotic
RNA of good quality is visualized as two distinct peaks on the electropherogram,
corresponding to the 18S and 28S fragments. Peaks occurring at other fragment sizes or
irregularity of peak shape may indicate degradation, or poor-quality RNA. An automated
gel image is also generated based on the results of the electropherogram, in order to

35

visualize the quality of the RNA sample as if it were run by a standard slab 1% agarose
gel electrophoresis.
2.11 Microarray
The microarray analyses were performed at the London Regional Genomics
Centre (LRGC), Robarts Research Institute, London, Ontario, Canada. An equal amount
of RNA from 3 male pups originating from 3 different litters was pooled for each of the
ethanol-exposed and control PND 14 expression arrays. For the PND 70 mice expression
arrays, 3 males bom from 2 different litters for the ethanol-exposed mice, and 3 males
from 3 different litters for the control mice were pooled in equal amounts for the purposes
of analysis. A biological replicate of each of these arrays was performed, again using 3
male mice coming from different litters for each of the treatment X age group
combinations. A 1 pi portion of the RNA from each mouse’s brain, at concentration 66.7
ng/pl, was combined with 1 pi portions of the same concentration, from the other two
mice in the same age and treatment group, totalling the 200 ng of RNA required for
hybridization to the GeneChip® Gene 1.0 Sequence Tag (Affymetrix, Inc., Santa Clara,
CA) for the expression assay. The gene-chips provided whole-transcript coverage of the
28,853 genes in the mouse genome, with each gene being represented by approximately
27 oligonucleotide 25-mer probes on the array, or 770,317 probes in total.
The RNA was first reverse transcribed to complementary DNA (cDNA) using the
T7-01igo (dT) Promoter Primer (Affymetrix, Inc., Santa Clara, CA). The cDNA is then
DNase treated and transcribed into complementary RNA (cRNA) in vitro, using the T7
RNA polymerase enzyme and biotin-labelled nucleotides. The cRNA is then amplified,
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purified, and fragmented for hybridization. The chip and hybridization cocktail are placed
into the 45°C Affymetrix GeneChip Hybridization Oven for 16 hours, allowing for ample
hybridization. The chips are then stained using Streptavidin-Phycoerythrin (SAPE) which
binds to the biotin molecules and emits a fluorescence when run through the GeneChip
Scanner 3000 7G (Affymetrix, Inc., Santa Clara, CA). The scanner outputs the raw
intensity values for each probe into a file, as well as an image of the probes which allows
visualization of the fluorescence.
Probe-level data-normalization is applied to the raw data file using the standard
PLIER signal-estimation algorithm (Hubbell, 2002). Subsequent statistical analyses (two
way ANOVAs) were performed using Partek Genomics Solution Software
(http://www.partek.com/).
2.12 Pathway Analyses
Genes that were determined to be significantly (p < 0.05) up- or down-regulated at
least 1.15-fold from the Microarray at either PND14, PND70, or both days, were
submitted to Pathway Express Console (Intelligent Systems and Bioinformatics
Laboratory, Detroit, MI). This online tool provided the biological pathways that involved
our implicated genes, and rank-ordered them by impact factor. A /?-value indicating the
significance of the each of the pathway findings was also generated by the Pathway
Express Console.
2.13 Semi-Quantitative RT-PCR
Three genes were chosen for the confirmation of Microarray results by real-time
reverse-transcription polymerase chain reaction (RT-PCR). This highly-sensitive
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procedure permits quantitative evaluation of the relative expression level of specific
genes in the brains of individual mice. Thus, we chose to examine the gene expression
levels for the 6 control and 6 ethanol-treated mice individually, in addition to a pooled
sample of each of the treatment groups.
Three genes that were found to be significantly down-regulated on PND70—
Grin2c, Gabra6, and Glral—were selected because they were implicated on the
Microarray and moreover, because they have known functions in learning, anxiety, and
neurological disorders. The expression values for each gene in the pooled control and
treatment groups were evaluated, after 3 replicates of each had been performed. The
expression values indicate the number of cycles in the PCR that it takes for the sample to
reach the threshold for that gene; a higher number of cycles indicates a lower amount of
expression of the transcript. If the expression values for the pooled samples for each gene
were determined to be significantly different between the treated and control mice, we
followed up with an analysis of the expression values in each individual mouse, to check
for between-group differences.
The High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was
used to convert total brain RNA to cDNA. This random-primer method for initiating
cDNA synthesis ensures that first strand synthesis occurs efficiently with all types of
RNA, and the kit prepares cDNA directly for quantitative PCR applications.
Complementary DNA was synthesized from 2 pg of total RNA per 20-pL reaction, each
of which contained 2.0pL 10X RT Buffer, 0.8pL 25X dNTP Mix (100 mM), 2.0pL 10X
RT Random Primers, l.OpL MultiScribe Reverse Transcriptase, and 4.2pL of DEPCtreated water. The RT-PCR thermocycler, GeneAmp PCR System 9700 (Applied
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Biosystems), conditions were 10 minutes at 25°C, 120 minutes at 37°C, 5 seconds at
85°C, followed by final extension at 4°C.
The Pre-Developed TaqMan^ Assay Reagents were utilized to detect the
expression of target sequences in the cDNA samples according to the supplier’s protocol.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a housekeeping gene involved in
the metabolism of glucose, was used as the standard endogenous control for
amplification, as its expression is not expected to differ between treatment groups, and
moreover, was not found to be differentially expressed between groups in the Microarray
analyses. Negative controls contained the experimental (target gene) and control
(GAPDH) primers mixed with RNase-ffee water instead of the cDNA. Conditions on the
Step One Real Time PCR System 2.0 (Applied Biosystems) followed the protocol
outlined by the supplier.
2.14 Statistical Analyses
All statistical analyses were performed with the Statistical Package for the Social
Sciences 16.0 software (SPSS, Inc., Chicago, IL, USA), in which a /7-value of < 0.05 was
selected as the criterion for significance. Two-way ANOVAs were performed for all
behavioural evaluations with the exception of maternal care behaviours, with treatment
group and sex included as factors. Means and standard error of the means (M ± SEM) are
reported for each variable. Student’s t-tests were used for gene expression analysis. Error
bars on graphs represent the standard error of the mean.
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3.1 Daily ethanol consumption is highly similar across pregnant and non-pregnant
C57 females
Thirteen females consumed ethanol and were brought to full term in pregnancy
and their average consumption per day was about 3.52 mL of 10% ethanol solution. This
EtOH consumption level is comparable to the levels of the non-pregnant females tested in
this study, who averaged 3.77 mL/day (Fig. 1).
3.2 Maternal care behaviours were not apparently affected by ethanol consumption
Eleven mothers (5 control, and 6 ethanol-exposed) were tested for maternal
responsivity on post-natal days 2 and 5. No significant group differences in mothers’
latencies to sniff a pup, retrieve the first, second, and third pups removed from the nest,
begin to rebuild the damaged nest, or to execute the crouching posture, were observed
between the mothers (Fig. 2).
There were also no significant differences between control and ethanol-exposed
mothers in the number of pups who had milk present in their stomachs from post-natal
day 2 until 6.
3.3 Influence of ethanol on litter size, pup mortality and pup weight

Twenty-one litters (8 control, and 13 ethanol-exposed) were evaluated for
mortality of pups during the course of this experiment. The total litter size (including both
live and still-born pups) on post-natal day 0 was not significantly different between
groups (control = 7.13 ± 0.23, treatment = 7.46 ± 0.60). However, significant differences
between control and ethanol-exposed litters were observed in the percentage of stillborn

Figure 1

The average daily consumption of 10% ethanol solution in pregnant and non-pregnant
C57 mice was 3.52 mL and 3.77 mL, respectively. The dashed line represents parturition.
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Figure 2

Bar graphs representing the average latencies (in seconds) of control and CPD females to
perform basic maternal care behaviours on post-natal day 2 and post-natal day 5.
(a) The latency to first locate and sniff a pup that had been removed from the nest on
post-natal day 2 (i) and post-natal day 5 (ii).
(b) The latency to retrieve the first pup that had been removed from the nest on post-natal
day 2 (i) and post-natal day 5 (ii).
(c) The latency to retrieve the second pup that had been removed from the nest post-natal
day 2 (i) and post-natal day 5 (ii).
(d) The latency to retrieve the third pup that had been removed from the nest on post-natal
day 2 (i) and post-natal day 5 (ii).
(e) The latency to begin rebuilding a damaged nest on post-natal day 2 (i) or post-natal
day 5 (ii).
(f) The latency to assume the crouching position over pups on post-natal day 2 (i) and
post-natal day 5 (ii).
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pups counted on post-natal day 0 (control = 1.79 ± 1.79, treatment = 14.40 ± 4.39) (F()>i9)
= 7.84,/? < 0.05), as well as the subsequent percentage of pups surviving until post-natal
day 7 (control = 91.06 ± 5.36, treatment = 66.21 ± 9.53) (F(i; i9) = 4.63,p < 0.05) and
post-natal day 21, calculated from the initial litter size (control = 89.28 ± 5.23, treatment
= 61.29 ± 9.95) (F(i( j9) = 7.90,/? < 0.05). (Fig 3.) There was a significant effect of
treatment group on pup weight on post-natal day 2 (control = 1.51 ± 0.03, treatment =
1.40 ± 0.03) (F(i; 63) = 4.77, p < 0.05) and post-natal day 21 (control = 8.14 ± 0.24,
treatment = 7.08 ± 0.20) (F(i>63) = 11.61, p < 0.005). There was no effect of sex on pup
weight during this period, nor a significant interaction between treatment and sex. (Fig 4.)
Thirty ethanol-exposed (males = 16, females = 14) and 35 control (males = 19,
females = 16) mice were investigated in the developmental and behavioural tests.
3.4 Developmental Milestones
For the 9 Developmental Milestones tested, significant differences between
treatment groups were found for the appearance of Negative Geotaxis (control = 5.49 ±
0.14, treatment = 6.07 ± 0.24) (F(i,63) —4.51, p < 0.05), Cliff Aversion (control = 4.74 ±
0.22, treatment = 6.90 ± 0.33) (F(i>63) = 0.86,/? < 0.05), Auditory Startle (control = 10.83
± 0.22, treatment = 11.93 ± 0.27) (F(i, 63) = 11.32, p < 0.005), and Air Righting (control =
12.83 ± 0.23, treatment = 13.73 ± 0.25) (F(i,63) = 7.53,/? < 0.01). There were no
significant between-groups differences for the day in which Surface Righting, Forelimb
Grasp, Ear Twitch, Open Field Traversal, or Eye Opening were achieved. There were no
significant differences between male and female pups for the acquisition of any of the
milestones tested, nor were there any treatment by sex interactions. (Fig 5.)

Figure 3

A series of bar graphs depicting the average litter sizes and survival rates of each
treatment group.
(a) The total litter size (including both live and still-born pups) on the day of birth was not
significantly different between groups.
(b) A larger percentage of ethanol-exposed pups were stillborn.
(c) A smaller percentage of ethanol-exposed pups were found alive on post-natal day 7.
(d) A smaller percentage of ethanol-exposed pups were found alive on post-natal day 21.
A single asterisk (*) indicates a level of significance ofp < 0.05, two asterisks (**)
indicate p < 0.01, and three asterisks (***) indicate p < 0.005.
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Figure 4

Bar graphs depicting the average weight of pups (in grams, g) on post-natal day 2 (a) and
post-natal day 21 (b). Males and females are combined because there were no sex
differences in weight during this period.
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Figure 5

Bar graphs representing the 4 developmental milestones that were delayed in ethanol
exposed pups, based on average day of acquisition.
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3.5 Behavioural Testing
a) Hypoactivity in the open field
In the open field arena there were significant differences in the activity level
between ethanol-exposed and control mice (control = 2458.10 ± 63.40, treatment =
2162.50 ± 62.69) (F(i>63) = 11.46,/? < 0.005), with control mice displaying higher levels
of activity in the novel situation. There were no significant differences between sexes in
the activity levels over the 15-minute period or between treatment groups or sexes in the
total distance travelled. There were no significant group differences in the number of
rears over the 15-minute period; however, there was a significant main effect of sex on
the number of rearing responses (males = 217.94 ± 8.64, females 175.55 ± 11.20) (F(i,63)
= 10.40,/> < 0.005). (Fig 6.)
The percentage of time that mice spent in the perimeter of the arena was another
parameter that differed significantly between treatment groups (control = 86.95 ± 0.68,
treatment = 89.85 ± 0.59) (F(i, 63>= 4.32,p < 0.05). Ethanol-exposed mice spent
significantly greater amounts of time in the outermost regions of the arena than control
mice did, whereas a difference was not found between the sexes in thigmotaxis. There
were no interactions between sex and treatment for any open field measures (Fig 7.)
b) Hypoactivity in the home cage test
During the overnight activity test, significant differences were observed in overall
activity levels between ethanol and control groups (F(i>63) = 8.07,/? < 0.01), as well as
between sexes (F(i,63) = 7.1 \ ,p < 0.01). The activity level as determined by the number

Figure 6

Bars represent various activity measures in the open field apparatus.
(a) The total activity over the 15-minute period, measured as the number of beam breaks
in the open field arena, was significantly lower in treated mice.
(b) Total distance travelled (in cm) over the 15-minute period did not differ between
treatment groups or between sexes.
(c) The average number of rears over the 15-minute period was significantly lower in
female mice.
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Figure 7

Bars representing the percentage of time spent on the edges of the open field apparatus.
Ethanol-exposed mice spent significantly more time displaying thigmotaxic behaviour.
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of beam breaks over the period was greater in control mice (males = 53783 ± 3079.4;
females = 67050 ± 2503.2) than in ethanol exposed mice (males = 48141 ± 4561.4;
females = 53183 ± 3293.1), as well, greater in females than males in both groups (Fig 8.)
There was a significant effect of treatment on the percentage of time spent resting
(F(i, 63)= 7.98,/? <0.01) and the percentage of time spend moving slowly (F(i>63) = 15.31,
p < 0.005), with control mice spending significantly less time resting (control = 85.71 ±
0.83, treatment = 88.96 ± 0.80) but more time moving slowly (control = 9.25 ± 0.49,
treatment = 6.66 ± 0.46) than ethanol-treated mice. (Fig 8.) The hourly pattern of activity
throughout the 12-hour testing period was highly similar between groups. (Fig 9.)
There were no significant differences between treatment conditions or between
sexes in the mean number of rears per minute, total distance travelled, or percentage of
time moving fast. There were no treatment by sex interactions present.
c) Increased anxiety in the elevated plus maze
There was a significant effect of treatment on the amount of time spent on the
open arms of the elevated plus maze over the 5-minute testing period (F(i; 28) = 5.64,/? <
0.05). Mice who had been exposed to ethanol prenatally spent significantly less time than
control mice on the open arms of the maze (control = 12.91 ± 2.84, treatment = 6.09 ±
1.60). There were no differences between sexes in time spent on open vs. closed arms of
the elevated plus maze, nor any interactions between treatment and sex. (Fig 10.)
d) Altered learning in the barnes maze
Training Days 1-4

Figure 8

Graphs indicating the activity levels of control and treatment group mice during the
overnight home-cage activity test
(a) Overall activity level as determined by the number of beam breaks over the 12-hour
period was significantly lower in ethanol-treated mice, and significantly lower in males.
(b) The percentage of time spent moving slowly was significantly lower in ethanol-treated
mice.
(c) The percentage of time spent resting was significantly higher in ethanol-treated mice.
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Figure 9

The activity over the 12-hour overnight home cage testing period determined by the
number of beam breaks, broken down by hour.
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Bar graphs representing the percentage of time spent on the open, anxiogenic arms of the
Elevated Plus Maze. Control mice spend significantly more time on the open arms than
the ethanol-treated mice.
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For the first training day of the Barnes Maze, there were significant differences
between treatment groups in the average latency to find the escape hole across the four
training trials (F(!>63) = 11.51,/? < 0.005), as well as in the average distance travelled
across the four trials (F(i>63)= 6.40, p < 0.05). Specifically, ethanol-exposed mice took
significantly longer to find the escape hole (control = 68.80 ± 5.33, treatment = 96.53 ±
6.45), and travelled significantly further atop the maze platform during the 3-minute
training trials (control = 3.37 ± .25, treatment = 4.39 ± .31). There was no difference
between treatment groups in the mean speed travelled in the four trials. There were no
differences between sexes or interactions for any of the testing variables of day 1.
On the second day of training, there was a significant difference between
treatment groups in the average latency to find the escape hole across the four training
trials (F ^ ^ ) = 7.27,/? < 0.05), with ethanol-treated mice taking significantly longer than
control mice to locate the escape hole (control = 27.49 ± 2.04, treatment = 38.22 ± 3.62).
There were no between treatment group differences on distance travelled or mean speed,
nor were any sex differences or interactions present on any of the testing variables for day
2 of training. (Fig 11.)
On day 3 of training, there were no between treatment group or between sex
differences or interactions on any of the testing variables evaluated.
On the final training day, there was a significant difference between treatment
groups in the latency to reach the escape hole across the four training trials (F(it 63) = 4.38,
p < 0.05), with ethanol-treated mice taking longer to find the hole than control mice

Figure 11

Bar graphs representing the four training days of the Barnes Maze.
(a) Average latency (in seconds) to reach the escape hole on each of the four training days
was significantly greater in ethanol-treated mice on 3 of the 4 days.
(b) Average distance (in m) travelled on each of the four training days was significantly
greater in ethanol-treated mice on the first day of training only.
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(control = 12.40 ± 1.06, treatment = 17.69 ± 2.38). There were no between treatment
group differences in distance travelled or mean speed; however, there was a difference
between sexes in the mean speed travelled on training day 4 (F(i; 63) = 6.26, p < 0.05),
with males travelling significantly slower than females (males - .0713 ± .00254, females
= .0824 ± .00420). There were no treatment by sex interactions present. (Fig 11.,12.)
When the training day 1 was broken down into the 4 trials, there was a significant
difference in the average latency to locate the target hole on the second (control = 67.88 ±
9.40, treatment = 110.76 ±10.15) (F(i, 63) = 9.62,/? < 0.005) and fourth trials (control =
40.80 ± 6.63, treatment = 63.23 ± 8.34) (F(i,63) = 4.54,/? < 0.05). (Fig 12.)
Probe Trial Days 5 and 12
On the first probe trial day, day 5, there was a significant difference between
treatment groups in the proportion of mice who entered the correct quadrant of the maze
(Northwest, NW) first (F(i; 63) = 4.35,/? < 0.05), with control mice being significantly
more likely to enter the quadrant containing the escape hole when first released in the
maze (control = 0.40 ± 0.08, ethanol = 0.17 ± 0.07). There was also a significant
difference between treatment groups in the percentage of time spent moving towards the
target hole (Fq, 63) = 6.28,/? < 0.05), with control mice spending significantly more time
moving towards the previous location of the escape hole (control = 19.54 ±0.81, ethanol
= 15.43 ±1.48). (Fig 13.)
On the second probe trial day, day 12, there was a significant difference between
treatment groups in mean number of entries to the correct quadrant of the maze (F(ii 63) =

Figure 12

Bar graphs representing the training days of the Barnes Maze.
(a) Average latency (in seconds) to reach the escape hole on the 4 training trials of
training day 1. Ethanol-treated mice took significantly longer to enter the target hole on
the second and forth trials.
(b) Average speed (in meters per second) travelled across the four trials on the fourth
training day, with males travelling significantly slower than females.
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Figure 13

Bar graphs representing the first probe trial day of the Barnes Maze.
(a) The percentage of mice who selected the correct quadrant for entry first on the first
probe day was significantly lower in ethanol-treated mice.
(b) Proportion of the probe trial spent moving towards the target hole location on the first
probe day was significantly lower in ethanol-treated mice.
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4.32, p < 0.05), with control mice entering the target quadrant significantly more often
than ethanol-exposed mice during the trial (control = 4.31 ± 0.27, ethanol = 3.63 ± 0.21).
There was a significant difference between treatment groups in the percentage of time
spent moving away from the target hole (F(i; 63) = 15.24,/? < 0.005), with control mice
spending significantly less time moving away from the escape hole location (control =
14.60 ± 0.42, ethanol = 17.71 ± 0.72). (Fig 14.)
There was a significant effect of sex on the average speed (F(i; 63) = 6.40,/? < 0.05)
and average distance travelled (F(i>63) = 6.46,/? < 0.05) on probe day 12, with males
travelling significantly slower than females (males = 0.10 ± 0.01, females = 0.12 ± 0.01)
and travelling significantly less distance over the trial (males = 5.99 ± 0.23, females =
6.93 ± 0.29).
3.6 Brain weight is drastically reduced in PND14 mice prenatally exposed to ethanol
There was a significant difference between treatment groups in the weight of male
mouse brains at PND 14 (F(i, io>= , p < 0.005) (control = 0.52g ±0.01, ethanol = 0.44g ±
0.01). On PND70, brains of male control mice were slightly heavier (control = 1.54g ±
0.02, ethanol = 1.50g ± 0.01); however, this difference did not reach significance. (Fig
15.)
3.7 All RNA samples were of adequate quality and quantity
All RNA samples met the minimum purity requirement of 1.80 for both the
260/280 and 260/230 ratios on the Spectrophotometer, as well as the minimum
concentration of 100 ng/pl. Additionally, the electropherogram results from the

Figure 14

Bars representing the second probe trial day of the Barnes Maze.
(a) Number of entries to correct quadrant on the second probe trial day was significantly
lower in ethanol-treated mice.
(b) Proportion of probe trial spent moving away from the target hole on the second probe
trial day was significantly greater in ethanol-treated mice.
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Figure 15

Bar graphs representing average weight (in grams, g) of male mouse brains at post-natal
day 14 and post-natal day 70.
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bioanalyzer indicated that all of our RNA samples were high quality, further confirming
the Spectrophotometer results. (See appendices B, C)
3.8 Many genes were significantly dysregulated in ethanol-exposed mice
Before data were analyzed, the Plier normalization was performed for signal
quantitation of the oligonucleotide array. List of genes were generated based on the
criteria of a minimum 1.15 fold change with p < 0.05 significance. 147 annotated genes
were found dysregulated on post-natal day 14, and 168 on post-natal day 70. (See
appendix D)
3.9 Various biological pathways involve our dysregulated genes
Based on the input dysregulated genes, the top 10 pathways, ranked by impact
factor (IF), implicated at both post-natal day 14 and 70 were examined for potential
associations between the short- and long-term effects of prenatal alcohol exposure. (Fig
16.) The neuroactive-ligand receptor interaction was implicated at both days, and
considered a focal point for future investigation. Three genes implicated in this pathway
were chosen for confirmation of differential expression by real time RT-PCR.
3.10 Real-time RT-PCR confirmed three of the dysregulated genes
The Glral, Grin2c, Gabra6 genes that were found to be significantly downregulated by the Microarray on post-natal day 70 were examined for differences
determined by real time RT-PCR. The expression values for the pooled samples of the 6
ethanol and 6 control mice indicated that all 3 genes (p < 0.005, p < 0.005,/? < 0.005)
were significantly down regulated in the ethanol-exposed group. (Fig 17.)

Figure 16.

Tables of the pathways implicated by Pathway Express based upon the dysregulated
genes on post-natal day 14 and 70.
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Dysregulated Pathways Implicated on Post-natal day 14

Rank Pathway Name
Neuroactive ligand-receptor
1 interaction
Complement and
2 coagulation cascades
Antigen processing and
3 presentation
4 Taste transduction
Autoimmune thyroid
5 disease
6 p53 signaling pathway
Maturity onset diabetes of
7 the young
8 Cell cycle
9 Asthma
10 Regulation of autophagy

Impact
Factor

#Pathway
Genes on
Chip

# Input
Genes

p-value

5.223

6

257 0.005391

4.628

3

71 0.009773

4.144

3
2

85 0.015866
60 0.053357

2.816
2.762

2
2

64 0.059818
66 0.063144

1.939
1.892
1.802

1
2
1
1

25 0.14387
111 0.150765
29 0.164898
32 0.180332

2.931

1.713

Dysregulated Pathways Implicated on Post-natal day 70

Rank Pathway Name
Amyotrophic lateral
1 sclerosis (ALS)
Neuroactive ligand-receptor
2 interaction

Impact
Factor

#Pathway
Genes on
Chip

#Input
Genes

p-value

6.556

4

57

0.001421

6.386

8

257

0.001685

3 Basal transcription factors

3.439

2
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0.0321

4 Cell cycle

2.667

3
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0.069432

5 PPAR signaling pathway
Jak-STAT signaling
6 pathway

2.052

2
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0.128514
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3

7 ECM-receptor interaction
Maturity onset diabetes of
8 the young
Toll-like receptor signaling
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Figure 17

Bar graphs indicating the expression level, indicated by number of cycles taken to reach
threshold, of the pooled control and treatment group mice at post-natal day 70.
(a) It took significantly more PCR cycles to reach the threshold for Girai expression in
the ethanol-treated mice.
(b) It took significantly more PCR cycles to reach the threshold for Grin2c expression in
the ethanol-treated mice.
(c) It took significantly more PCR cycles to reach the threshold for Gabraó expression in
the ethanol-treated mice.
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Based on analyses of the individual mice, both the Grin2c and Glral genes were
confirmed as significantly downregulated (p < 0.05, p < 0.05); however, the Gabra6 gene
only approached significance {p = 0.0798). One ethanol-exposed mouse was excluded
from the Gabra6 analyses because it displayed a complete absence of Gabra6 expression,
despite multiple replications and confirmation of technical accuracy and quality assurance
measures. (Fig 18.)

Figure 18

Bar graphs indicating the expression level, indicated by number of cycles taken to reach
threshold, of the individual control and ethanol-treated mice.
(a) Individual levels of expression of the Glral gene in control and ethanol-treated mice.
(b) Individual levels of expression of the Grin2c gene in control and ethanol-treated mice.
(c) Individual levels of expression of the Gabra6 gene in control and ethanol-treated mice.
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CHAPTER 4. DISCUSSION
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A substantial body of evidence supports the notion that the consumption of
alcohol-containing beverages during pregnancy can result in broad and severe teratogenic
effects in developing offspring. However, the genetic, cellular, and physiological
mechanisms that underlie these aberrant processes are poorly understood. A major
difficulty in this field of research has been the ability to establish a reliable and valid
animal model of FASD, one that will consistently respond to prenatal ethanol insults in a
manner similar to that of humans as evidenced by similarities in physical, physiological,
and behavioural manifestations of the disorder. Various animal models have been
developed, each with its own advantages and drawbacks, but none of which are alone,
able to account for the variability in phenotypic outcome observed in humans. The
present study sought to evaluate a novel approach to modelling FASDs in animals, in the
hopes that it would complement the existing models of this disorder and provide unique
advantages to the study of FASDs.
The second aim of this study was to use this model to investigate the underlying
molecular mechanisms involved in the etiology of FASD with special attention to the
changes in gene expression that occur both shortly and more long-term, following
prenatal ethanol insult.
The results of this study suggest that a number of genes are affected by chronic
ethanol exposure that occurs throughout the 3 human trimester equivalents of mouse
development, many of which are involved in crucial neurodevelopmental processes and
thus, may serve as candidate genes for future research on the mechanisms of prenatal
ethanol teratogenicity. This information may provide novel targets for future
pharmacotherapy.
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4.1 Continuous preference drinking by C57BL/6J mice as a novel animal model of
Fetal Alcohol Spectrum Disorders
In the present study, the use of the C57BL/6J mouse strain was purported to be a
novel and plausible step towards the development of a mouse model of FASD through the
use of a continuous drinking paradigm. This proposal was informed by previous reports
of this strain’s human-like susceptibility to the morphological, physiological, and
behavioural components of ethanol teratogenesis, as well as reports of their propensity for
biologically-relevant consumption of ethanol-containing solutions.
We found that pregnant C57 females continue to drink appreciable levels of
ethanol-containing solutions throughout gestation and the post-natal period. The average
daily consumption of these dams was 3.52 mL/day, which translates to about 13.15g/kg
of EtOH per day (SEM ± .20) based on the starting weights of the mice. This volume is
highly similar to that reported by previous descriptions of female C57’s (Allan et al.,
2003; Loney et ah, 2003; Kaminen-Ahola et ah, 2010) and amounts to an approximate
daily consumption difference of 7% from the non-pregnant females in this study, who
consumed 3.77 mL/day (or about 70% of their total intake including water, 5.52 mL/day).
We project that the average daily peak blood alcohol level was close to 120 mg/dl, based
on the reports of previous studies linking consumption to BAL in pregnant female C57s
(Allan et ah, 2003; Caldwell et ah, 2008). The University of Washington’s 4-Digit
Diagnostic Code considers maternal blood alcohol concentrations of 100 mg/dl to
represent children who are at “high-risk” for FASDs, and thus, although this level is not
as substantial as those achieved by injection exposure paradigms (>200 mg/dl), it is still
considered relevant to human consumption and risk for FASD (Coles et ah, 1985). In fact,

89

mild-moderate human consumption of alcohol during pregnancy has been associated with
higher risk for spontaneous abortion (Harlap and Shiono, 1980), decrements in birth
weight (Windham et al., 1995), and even mental health problems in children of school
age (Sayal et al., 2007).
It is interesting to note that there was an unexpected decrease in consumption
levels of the pregnant females during days 9 through 13 of gestation. This was a
behaviour that was highly consistent across the females; however, the reason for this
decrease is unknown and should be explored further in future continuous preference
drinking studies.
Several maternal care behaviours were evaluated for the possibility that ethanol
consumption might negatively impact the quality and/or quantity of care provided by
dams to their litters. Although we did not observe any differences in the retrieval tests or
latencies to nest-build and crouch, it is possible that there were more subtle differences
between the control and ethanol-consuming mothers that were unapparent to us by this
evaluation. For example, Chen and colleages (1982) measured the latencies of ethanol
exposed rat pups to attach to the nipples of dams and compared these latencies to those of
control pups. The investigators found that from post-natal day 0 to post-natal day 9,
ethanol-exposed pups took significantly longer to attach to the nipple and begin feeding, a
characteristic reported in human infants with prenatal alcohol exposure (Martin et al.,
1979). Difficulty in attaching to the nipple could account for post-natal growth deficits
due to undemutrition, however, this could not explain the pre-existing weight deficits that
existed in the pups at birth in both the Chen (1982) study and the present one. Moreover,
a cursory measure of maternal feeding was taken with pups being examined for the
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presence of milk in their stomachs on post-natal days 2 until 6, and no differences were
found between groups in the frequency of unfed pups.
In contrast to some rodent FASD-model studies, we did not utilize a control group
receiving a liquid solution isocaloric to the 10% ethanol solution for a number of reasons.
Firstly, in studies where isocaloric and pair-fed control groups are employed, they are
generally identical to ad-libitum control groups in terms of the behavioural and
physiological outcomes related to fetal alcohol exposure. For example, indices of
offspring weight (Abel et al., 1978; Simpson et al., 2005), anxiety level (Dursun et al.,
2006), activity level (Becker and Randall, 1989; Tran et al., 2000; Wang et al., 2009), and
even neural correlates such as the differentiation and migration of neurons (Zhou et al.,
2001) and the vulnerability of neuronal populations to ethanol-induced cell loss in various
brain structures (Bonthius and West, 1991) showed no differential effects between
controls and isocaloric or pair-fed diets. Secondly, there is evidence that various species
of rodents perform what functions as a “calorie control” mechanism when presented with
ethanol solutions for extended periods which may be, in part, due to the anorexic effect of
ethanol (Aguiar et al., 2004). These rodents decrease their food intake such that their total
daily caloric intake is not significantly different from rodents not receiving ethanol, and in
particular, this phenomenon has been reported in the C57BL/6J strain that we are
studying (Wiebold & Becker, 1987). Lastly, we have adopted the continuous-preference
drinking model to more closely approximate the pattern of drinking observed in women
who drink alcohol regularly, as opposed to in a ‘binge’ or episodic fashion, and this
includes alcohol-dependent women—the highest risk population for bearing offspring
with FASD (Stratton et al., 1996). Individuals who drink moderately on a daily basis
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often display a similar stability in caloric intake because of decreased food intake, so that
total daily caloric intake is not significantly greater in this population than in occasional
or non-drinkers (Lieber, 2003; Manari et al., 2003). Despite being equivalent calorically,
a diet containing more ethanol-derived calories than those from food sources will result in
nutritional differences simply by virtue of having less intake in the form of food; yet, the
nutritional deficits our mice experience as they acquire a disproportionate number of
calories through the alcohol they consume may be similar to that observed in women who
display this drinking pattern throughout pregnancy. Even if we were to control for the
lessened nutrition from food intake by pair-feeding dams, alcohol alone causes secondary
nutritional deficits by interfering with the absorption of vitamins (Lieber, 1994), and this
occurs to an extent of which has yet to be quantified.
Whether or not exposure through maternal milk consumption during the third
trimester equivalent would be robust enough to induce deficits in offspring was one of the
initial inquiries of this investigation. Although there are currently no tests sensitive
enough to detect these nominal blood alcohol levels in pups, it is known that ethanol
enters milk in both rodents and humans (Ness et al., 1990; Subramanian, 1999; Mennella
& Beauchamp, 1997), and is capable of causing subsequent adverse effects to the child
(Mennella et al., 2005). Most studies point to the third trimester as most important for the
development of the hippocampus in both humans and rodents (Livy et al., 2003 ; Coles,
1991), a structure known to be critical for memory and learning—especially spatial
learning (O’Keefe and Nadel, 1978). Disruptions to normal hippocampal development by
ethanol exposure have previously been associated with memory deficits in both rodent
and human offspring (Berman and Hannigan, 2000) and several mechanisms for this have
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been proposed (Lovinger et al., 1989; White and Best, 2000; Iqbal et al., 2004). Our
observations of altered learning and memory in prenatally-alcohol exposed mice suggest
that there may have been significant disruptions to the hippocampus via alcohol exposure
during the third trimester, however, since exposure was not limited to the third trimester
equivalent, the effects of ethanol exposure during the first and second trimesters cannot
be ruled out as sole or partial contributors.
4.1.1 Growth deficits, neo- and post-natal mortality, and developmental delays in
prenatally exposed neonates
There is an abundance of evidence supporting the notion that prenatal ethanol
exposure is capable of causing growth restrictions in rodent models of FASD. Both rats
(Sandor and Amels, 1971; Abel et al., 1978; Lopez-Tejero et al., 1986) and mice (Datta et
al., 2008; Middaugh et al., 1991; Sluyter et al., 2005) have displayed these growth
deficits, however the timing of the growth delay—whether present at birth, at weaning, in
adulthood, or some combination of these periods—varies greatly between studies. The
present study found that mice exposed to ethanol throughout gestation displayed weight
deficits at birth that continued to persist until weaning (post-natal day 21); however, this
deficit did not extend until the mice reached adulthood at post-natal day 70. In humans
with FASD, growth deficits are observed at birth, often present throughout childhood and
adolescence, and may even extend to adulthood (Day et al., 2002; Streissguth et al.,
1991). It is possible that a more binge-like ethanol exposure regimen would have been
able to induce growth deficits that would last until adulthood in mice.
As with various other studies of rodent prenatal ethanol exposure, the present
study found no difference in the number of pups bom to ethanol-consuming or control

93

dams (Kahn, 1968; Martin et al., 1977); however, the viability of the pups was drastically
impacted by prenatal alcohol exposure. Not only were there more stillboms in the
ethanol-exposed litters, but also, a significantly greater proportion of ethanol-exposed
pups died before weaning on post-natal day 21, findings that are in line with many other
rodent models of FASD (Abel et al., 1978; Bielawski et al., 1997), and may also be true
of human infants (Burd et al., 2004; Hoyert, 1996; King and Fabro, 1983). We also found
that the rate of pregnancy was greatly reduced in ethanol-consuming mothers, with only
39% of the matings resulting in pregnancies in contrast with 60% of the control matings.
There are many alcoholic women, as well as moderate drinkers, who report difficulties
with fertility (Sokol et al., 1980; Grodstein et al., 1994), and it appears that there is a
corresponding impediment in rodents when alcohol is regularly consumed (Randall and
Taylor, 1979).
Prenatal alcohol exposure has been related to infant delays in the achievement of
reflexes (Staisey & Fried, 1983; Jacobson, 1998), motor development (Kyllerman et al.,
1985; Kalberg et al., 2006), and coordination (Church et al., 1997); however, these
variables have received less attention in the animal literature than other behavioural
indices. Recently, a protocol was developed which outlines the procedures for evaluating
the normal developmental trajectory of the C57BL/6J mouse strain (Hill et al., 2007), and
we utilized this strain-specific battery to examine if the neurodevelopment of our ethanol
exposed neonates was disrupted in ways comparable to that of human infants with FASD.
We observed various delays including the attainment of negative geotaxis and air righting
reflexes, both of which are milestones that have been observed as delayed in ethanoltreated rats (Lee et al., 1980; Shaywitz et al., 1979), and both of which involve the proper
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and timely development of reflex, motor ability, and coordination (Endres, 2005).
Moreover, we found that our mice displayed deficits in the auditory startle response,
taking significantly longer to develop this reflex than control mice, a finding corroborated
by other rodent studies of FASD (Gottesfeld and Silverman, 1990). It is possible that
prenatal ethanol exposure interferes with the developing auditory system in mice, as it is
reported to do in humans (Church et al., 1997), which could account for the pronounced
delay in the development of this reflex in our mice.
4.1.2 Altered activity, anxiety, and learning in adolescence and adulthood of
prenatally ethanol exposed mice
A human characteristic less consistently replicated in animal models of FASD is
hyperactivity. Although many reports exist of increased spontaneous locomotor activity
of rodents in an open field (Becker and Randall, 1989; Tran et al., 2000; Gibson et al.,
2000), nearly as many studies report no effect of prenatal treatment (Downing et al.,
2009; Allan et al., 2003; Dursun et al., 2006; Mothes et al., 1996), or even report the
opposite effect (Wang et al.,2009; Wilcoxon et al., 2005). This discrepancy has been
attributed to differences in the timing of ethanol exposure, with late gestational and post
natal alcohol exposure more frequently associated with increased levels of activity (Riley
et al., 1986). However, the present study, which involved ethanol exposure throughout
gestation as well as during the post-natal period, found that mice were hypoactive at 2
time-points and under 2 different conditions—a spontaneous open field and an overnight
home-cage activity test. It is possible that the chronic, albeit less acute, maternal self
administration from our continuous preference drinking model caused motor impairments
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significant enough to hamper activity, although this is a notion that must be explored
further.
The mice in this study showed elevated anxiety at two different time points and in
two different behavioural apparatuses. This is consistent with literature indicating the
ability of ethanol to alter stress-related variables in rodents prenatally exposed to alcohol.
For instance, rats display greater anxiety-like behaviour on the elevated plus maze when
they have been exposed to ethanol prenatally, measured as decreased time spent on the
open, anxiogenic arms of the maze (Dursun et al., 2006; Hellemans et al., 2008).
Moreover, testing on the elevated plus maze has been associated with the elevation of
serum corticosterone levels in rats and mice exposed to alcohol prenatally (Glavas et al.,
2001; Osborn et al., 1998), which may indicate an increased responsivity to stress in this
population. Alterations in the activity of the hypothalamic-pituitary-adrenal (HPA) axis
have been observed following prenatal ethanol exposure (Pamenter and Boyden, 1984;
Kang et al., 2004; Weinberg et al., 1996) and are likely to be related to the increased
susceptibility of adolescents and adults with FASD to anxiety-disorders and depression,
(O’Connor et al., 2000; O’Connor et al., 2002; Famy et al., 1998) both of which have
been associated with dysregulated or hyper-responsive HPA axis activity.
Cognitive-behavioural impairments in children exposed to ethanol in utero are the
most commonly reported problem in this population, occurring even in the absence of any
physical features or growth delays (Uecker and Nadel, 1998; Mattson et al., 2001;
Mattson et al., 1998). Most animal models have been able to reproduce the learning and
memory deficits following prenatal exposure to ethanol, with special attention to spatiallearning deficits, as these are widely observed in children with FASD (Dumas and Rabe,
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1994; Kim et al., 1997; Matthews and Simon, 1998; Uecker and Nadel, 1996; Summers et
al., 2008). The present study corroborated findings of other studies with prenatally
alcohol exposed C57BL/6J mice, in that learning and memory impairments were evident
when compared with control mice. However, the mice in this study were not totally
impaired; they still appeared able to learn the required escape route in the Bames maze,
indicated by decreasing average latencies to reach the target hole over training days, and
as well, they seemed to preferentially arrange themselves at its location on the probe trial
days. The deficit in this case appeared to be that of a slower acquisition of task-learning,
rather than an absolute absence of the ability to form associations.
4.2 The CPD paradigm can be used to study the molecular mechanisms underlying
FASD phenotypes
Observations of the interspecies similarities of human and CPD-generated FASD
traits strengthen its face validity and suggest that it may be a useful model for future
investigations into the molecular mechanisms of FASD. Thus, we opted to go forward
and use this model to explore the hypothesis that many of the phenotypic abnormalities in
FASD may be mediated by changes in the expression of genes that are important for
growth, neurodevelopment, and behaviour.
4.3 Ethanol exposure during the three trimester equivalents causes changes in the
expression of genes in the developing mouse brain that persist until adulthood
A limited number of studies have looked at the impact of prenatal ethanol
exposure on the subsequent regulation of genes in offspring, and many of the studies that
have, have utilized whole-embryo samples to evaluate gene expression, rather than
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focusing on a particular structure (Liu et al., 2009). There are a couple exceptions, with
studies that have examined fetal brains for changes in gene expression (Hard et al., 2005,
Toso et al., 2006); however, these studies have used injection-type models of ethanol
exposure, reflecting the effect of ethanol on only 1 or 2 days of gestation. The present
study examined whole-brain tissue from mice at two developmental time periods to
evaluate the short and long-term effects of moderate exposure to ethanol throughout the
three-trimester equivalents. To our knowledge, we are the first study to examine the
effects of chronic, self-administered ethanol intake on the differential expression of genes
in the resulting offspring’s brain.
The second most significant pathway implicated by the dysregulated genes of 70
day-old mice was the neuroactive ligand-receptor interaction pathway. This pathway is
involved with a number of neuropsychiatrie conditions, including depression and anxiety,
and has been implicated as a potential pathway involved in alcohol dependence (Guo et
al., 2010). Many of the receptor and signalling molecules of this pathway are known to be
affected by ethanol exposure (Iqbal et al., 2004; Samudio-Ruiz et al., 2010; Engblom &
Âkerman, 1991), and additionally, have associations with learning, memory, and neuro
motor deficits (Toso et al., 2006; Morris, 1989; Hirzel et al., 2006). This pathway was
also implicated in the 14 day-old mice, making it the only pathway that achieved
significance as being dysregulated at both timepoints and thus, may represent a common
disrupted pathway involved in the deficits observed from infancy to adulthood in FASDs.
The only pathway more significantly implicated than the neuroactive ligand-receptor
interaction pathway was the amyotrophic lateral sclerosis (ALS) pathway on post-natal
day 70. ALS is a condition marked by progressive neurodegeneration of motor neurons in
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the brain and spinal cord, and is associated with oxidative stress and disruptions of
normal apoptotic processes (Barber et al., 2006; Estevez et al., 1999). It is possible then,
that some of the molecular mechanisms that underlie the neuropathology of FASD are
also common to that of ALS.
4.4 Other implicated genes
Besides those implicated in the neuroactive ligand-receptor interaction pathway,
we observed a number of additional genes to be up- or down-regulated in the brains of 14
and 70 day old mice. In the former group, there was upregulation in genes that have been
associated with apoptotic neuronal cell death including the potassium voltage-gated
channel, isk-related family, member 3, or Kcne3 (Pannaccione et al., 2007) and the SET
translocation gene, Set (Fan et al., 2003; Beresford et al., 2001). Set, and interferon alpha
6, Ifna6, are two genes that have roles in cell cycle control (Canela et al.,2003;
Tiefenbrun et al., 1996) and were both upregulated 1.29 on day 14, as well. Additionally,
various genes related to cell cycle control, chromatin remodelling, neural differentiation,
olfaction, and transcription were differentially expressed on post-natal day 14.
In the older group of mice, there were many dysregulated genes that seem likely
future candidate genes in studies of FASD. The Zinc finger protein of the cerebellum 2,
Zic2, was downregulated -1.33 in ethanol-treated mice. Disruptions of this gene have
been associated with holoprosencephaly (Roessler et al., 2009; Brown et al., 1998), spina
bifida (Nagai et al., 2000), and other central nervous system dysfunctions. The Zic2
protein is highly expressed in the cerebellum, and is considered crucial for normal brain
development (Aruga et al., 2002; Nagai et al., 2000). The paired box gene 6, Pax6, was
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another gene downregulated by -1.28 fold, and is involved with central nervous system
development and regulation of transcription (Quinn et al., 2007; Bishop et al., 2002).
Defects in Pax6 have been observed in individuals with cerebellar ataxia and movement
disorders, mental retardation, and aniridia of the eye (Davis et al., 2008; Graziano et al.,
2007). Mice with disrupted Pax6 expression display difficulties with sensorimotor
integration, and both short- and long-term memory (Tuoc et al., 2009). Two precursors to
cerebellin, cblnl and cbln3 were downregulated (-1.30 and -1.47, respectively) in
ethanol-exposed mice. Cerebellin is a protein that has been implicated in long-term
potentiation, central nervous system development, and synaptic homeostasis, and mice
with low levels of cerebellin show developmental anomalies associated with a loss of
cerebellar granule neurons (Miura et al., 2006; Yuzaki, 2008; Morgan et al., 1988).
Another major cerebellar gene, carbonic anhydrase 8, Car8, involved in both motor
control and synaptogenesis, was downregulated -1.32 (Jiao et al., 2005; Hirasawa et al.,
2007). The abundance of FASD-relevant developmental functions of these genes,
strongly suggests they may be critically involved in the etiology of this disorder.
Interestingly, two genes, Glral and Slc6a5, were significantly downregulated at
post-natal day 70 (-1.43 and -1.65), and disruptions of both have been implicated as the
cause of hyperekplexia, a neurological disorder associated with altered motor and startle
response capabilities. Genes involved in cell cycle control and apoptotic cell death were
also implicated. We found that the expression of the pituitary-specific positive
transcription factor 1, Poulfl, was upregulated 1.28 in ethanol-exposed mice at post-natal
day 70. In conjunction with this upregulation, we observed a huge overexpression
(>10fold) of Growth Hormone (GH) and Prolactin (PRL) in these mice, both of which are
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genes known to be activated by the Poulfl transcription factor (Nelson et al., 1988).
Many studies have shown that in situations of acute stress, central and peripheral neuronal
pathways can be quickly activated and cause a surge of pituitary and adrenal hormone
release in the brain (Kant et al., 1987; Rivier and Rivest, 1991; Tsigos and Chrousos,
2002). Prolactin secretion has been observed to be greatly increased immediately
following stressful situations in both humans and rodents (Meyerhoff et al., 1988; Smith
et al., 1977); growth hormone secretion has been found to be increased in response to
stress in humans and other primates (Miyabo et al., 1976; Meyer et al., 1967); however,
the results have not been as consistent in rodents (Rice et al., 1975; reviewed in Harvey et
al., 1995). It is thought that surges in pituitary hormones following stress may be the
result of rapid increases in hypothalamic-pituitary-adrenal axis activity (reviewed in
O’Connor et al., 2000). As these ethanol-exposed mice displayed increased levels of
anxiety in our experiments and because HPA axis dysregulation is reported in both
humans and animal models of FASD, it is possible that the large increase of both PRL
and GH is due to the abrupt restraint and novel-environment stress that is experienced just
minutes prior to their sacrifice.
4.5 Conclusions
The development of a useful animal model of FASD is complicated by the
phenotypic heterogeneity of the condition in humans and is perhaps, best accounted for in
multiple animal models each representing a particular point along the FASD spectrum. In
the present study, severe morphological abnormalities were not observed in offspring, and
although some degree of growth retardation was evident in neonates and young mice, this
deficit did not persist into adulthood. Cognitive and neurobehavioural deficits were
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apparent in this population, although severe mental retardation appeared unlikely. This
constellation of features suggests that perhaps the CPD paradigm of FASD will best serve
as a model of children who present with the cognitive-behavioural manifestations of
FASD without the gross physical anomalies or profound mental deficiencies.
In any animal model of human behaviour, the validity of said model is an
important consideration for evaluating the usefulness of the particular investigation. The
CPD model appeared to have face validity, as many similar characteristics to those in
children with FASD were noted in the ethanol-exposed mice, and in this way, the
treatment group “resembled” the human condition superficially. However, face validity is
only one type of validity and is considered less important than many other types of
validity because there is no sound basis for assuming that a condition should reveal itself
in animals in identical ways to that in humans (Hinde, 1976). The apparatuses used in this
study to measure activity, anxiety, learning, and memory were carefully selected because
each is supported by a body of evidence supporting its ability to investigate the particular
processes. Both the construct and predictive validity have been supported for the open
field test as a measure of activity and anxiety (Gould et al., 2009; Denenberg, 1969), the
home cage test as a measure of circadian activity (Visser et al., 2006; Tang et al., 2002),
the elevated plus maze as a measure of anxiety (Maximino et al., 2010; Pellow et al.,
1985), and the bames maze as a measure of spatial learning and memory (Koopmans et
al., 2003; O’Leary & Brown, 2009). Moreover, our replication of parallel findings
between separate behavioural tests which purport to examine the same construct,
including hypoactivity in both the open field and home cage tests, and increased anxiety
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in the open field test and elevated plus maze, lends further support to the validity of these
measures for these phenotypes.
4.6 Future Directions
There are limitations of the current study which may be of interest for future
studies involving the analysis of changes of gene expression in the mouse brain. For
instance, the present study performed whole-brain analyses of gene expression, which
does not permit any conclusions about changes in any particular brain structure. However,
region-specific dissection is challenging because of difficulties with the neuro-anatomical
resolution of the tiny mouse brains and moreover, slight variability in dissection
techniques can result in differential inclusion of cell types in the dissected region, even
with the same investigator. Perhaps more sensitive and precise technology will permit the
accurate micro-dissection of mouse brains in the future, allowing for better spatial
resolution of gene expression differences in the brain.
It is our hope that the progression to a more refined understanding of the
pathophysiology in FASD will ultimately guide therapeutic innovations to help victims of
the disorder. At this point in time there are no treatments or specific diagnostic tools for
recognizing FASD in infants, and lack of intervention may exacerbate the deficits
experienced over time. Current research with animals indicates several promising
treatment approaches, including the in utero supplementation of nutrients, neurotrophic
factors, or hormones (Summers et ah, 2008; Serrano et ah, 2010; Incerti et ah, 2010;
Endres et ah, 2005; Xu et ah, 2007), which have been able to ameliorate certain
abnormalities in ethanol-exposed offspring. If the results from the present study and
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similar works are consistent in determining genes that are differentially expressed
following prenatal exposure to ethanol, there is a potential to develop pharmacological
treatments to target the specific genes and areas implicated in the disease.
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N o v e m b e r 1, 200®
T h i s is the 2 n d R en ew a l o f this protocol
*A Full Protocol submission will be required in 2011

Dear Dr. Singh:
Your Animal U se Protocol form entitled:
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has had its yearly renewal approved by 1he Animal U se Subcommittee.
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t . Th is number must be indteated when ordering ari mats for this project
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
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scientific peer review be performed by the Animal Use Subcommittee office.
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Appendix B
Sample ID
20. IE
20.3E
23.IE
23.2E
24. IE
24.2E
21.1C
21.2C
22.1C
22.2C
27.1C
27.2C
18.IE
13.IE
13.2E
13.6E
13.7E
13.8E
8.1C
8.3C
15.5C
15.6C
16.1C
16.2C

ng/pL
A260
1345.1 33.628
18.622
744.9
932.3
23.308
1215.98 39.399
1191.67 29.792
1076.72 26.918
1044.49 26.112
1503.12 37.578
881.58 22.039
2451.92 61.298
1069.71 26.743
1898.85 47.471
1504.26 37.607
760.37 19.009
19.162
766.47
999.59
24.99
280.04
7.001
2767
69.175
467.13
11.678
326.43
8.161
2027.61 50.69
428.7
10.718
797.1
19.927
784.63
19.616

A280
17.1
9.453
11.516
14.997
14.596
13.424
12.739
18.643
10.764
30.253
13.157
23.344
18.762
9.724
9.269
12.554
3.682
35.771
6.01
4.279
24.482
5.529
9.917
9.699

260/280 260/230
1.97
1.93
1.97
1.81
2.02
2.31
2.07
2.03
2.04
2.32
2.01
1.80
2.19
2.05
2.02
1.82
2.05
2.29
2.03
2.28
2.03
1.83
2.32
2.03
2
1.94
1.95
1.96
1.97
2.07
1.99
1.96
1.9
2.26
1.93
2.19
1.94
2.19
1.91
2.03
2.07
2.3
1.94
1.81
2.01
2.34
2.02
2.33
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Appendix C

PND 14: Control #1

PND 14: Control #2

PND 14: Control #3

PND 14: Control #4

PND 14: Control #5

PND 14: Control #6
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PND 14: Treatment#!

PND 14: Treatment #2

PND 14: Treatment #3

PND 14: Treatment #4

PND 14: Treatment #5

PND 14: Treatment #6
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PND 70: Control #1

PND 70: Control #2

PND 70: Control #3

PND 70: Control #4

PND 70: Control #5

PND 70: Control #6
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PND 70: Treatment #1

PND 70: Treatment #2

PND 70: Treatment #3

PND 70: Treatment #4

PND 70: Treatment #5

PND 70: Treatment #6
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Appendix D

GeneAssignment
AK031561 // Set // SET translocation // 2 B // 56086 //,
AK054400 // Set // SET
BC004573 // Prpfl8 // PRP18 pre-mRNA processing factor 18
homolog (yeast) // 2 A
XR 035589 // Pramel // preferentially expressed antigen in
melanoma-like // X FI
XM 914534 // Lrit3 // leucine-rich repeat, immunoglobulin
like and transmembrane
NR 004051 //Btnl5 //butyrophilin-like 5//17Bl|17 18.7 cM
/ / 81497
NR 003634 // Rps4y2 // ribosomal protein S4, Y-linked 2 // 6
G 3//66184
NR 001579 // Terc // telomerase RNA component // 3 F/G //
21748
NM 212457 // Bex4 // brain expressed gene 4 // XE3|X //
406217 III ENSMUST000001
NM 207229 // Plac9 // placenta specific 9 / / 14 B // 211623 III
BC032982 // Plac
NM 207021 // Tas2rl 17 // taste receptor, type 2, member 117
// 6 Gl 6 63.5 cM//
NM 206871 // Ifha6 // interferon alpha 6 // 4 C4 4 42.6 cM //
15969///NM 20687
NM 206868 // V1rd 13 // vomeronasal 1 receptor, D13 // 7 A3
/ / 232959///ENSMUST
NM 205819 // Tiri 1 // toll-like receptor 11 // 14 Cl // 239081
III ENSMUST000000
NM 201611// H2-M10.6 // histocompatibility 2, M region
locus 10.6//17B1//3
NM 201370 // Wee2 // WEE1 homolog 2 (S. pombe) // 6 B1
// 381759 III ENSMUST0000
NM 199154 // Tas2rl07 // taste receptor, type 2, member 107
/ / 6 F3 6 62.0 cM//
NM 183322 // Khdcla // KH domain containing 1A / / 1 A4 //
368204 III ENSMUST0000
NM 181753 // Opn5 // opsin 5 // 17 B3 // 353344 III
ENSMUST00000068355 // Opn5 /
NM 181275 // Tas2rl39 // taste receptor, type 2, member 139
// 6 B2.1 // 353148
NM 177636 // H2-M1 // histocompatibility 2, M region locus
1 // 17 B1 // 224756
NM 177600 // Ccdc73 // coiled-coil domain containing 73 // 2
E2//211936///EN
NM 177123 // Spef2 // sperm flagellar 2 // 15 Al // 320277 III
ENSMUST0000004184

Gene
Symbol

p-value

Foldchange

Set

0.029055

1.285

Prpfl8

0.005122

1.310

Pramel

0.036282

-1.203

Lrit3

0.014209

1.355

Btnl5

0.044528

-1.267

Rps4y2

0.049741

1.217

Terc

0.039303

1.177

Bex4

0.033401

1.171

Plac9

0.015176

1.151

Tas2rl 17

0.035846

1.463

Ifna6

0.042203

1.286

Vlrdl3

0.014835

1.199

Tiri 1
H2M10.6

0.015573

1.393

0.049986

1.265

Wee2

0.02961

1.218

Tas2rl07

0.005107

1.231

Khdcla

0.028329

-1.210

Opn5

0.011716

1.213

Tas2rl39

0.011025

1.156

H2-M1

0.047438

1.355

Ccdc73

0.001448

1.259

Spef2

0.003094

-1.149
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NM 176942 // Gabra5 // gamma-aminobutyric acid (GABA)
A receptor, subunit alpha
NM 175391 // Apol7c // apolipoprotein L 7c // 15 El //
108956 III ENSMUST0000006
NM 175384 // Cdca2 // cell division cycle associated 2 / / 14
D1 // 108912///NM
NM 175305 // Lrrcl9 // leucine rich repeat containing 19 // 4
C5 // 100061 III E
NM 175000 // Hbql // hemoglobin, theta 1 / / 11 A4 // 216635
III ENSMUST000000205
NM_172527 //Nudtl5 //nudix (nucleoside diphosphate
linked moiety X)-type motif
NM 172435 // P2ryl0 // purinergic receptor P2Y, G-protein
coupled 10 // X D // 7
NM 172297 // Ccdc9 // coiled-coil domain containing 9 II1
K ill 243846 ///NM 0
NM 153123 // Atf7ip2 // activating transcription factor 7
interacting protein 2
NM 153087 // Hrh4 // histamine receptor H4 / / 18 A1 //
225192 III ENSMUST0000004
NM_ 152811 // Ugt2bl // UDP glucuronosyltransferase 2
family, polypeptide B1 // 5
NM 146240 // Rassf9 // Ras association (RalGDS/AF-6)
domain family (N-terminal)
NM 146050 // Oitl // oncoprotein induced transcript 1 // 14
A1 // 18300///ENSM
NM 145467 // Itgbll // integrin, beta-like 1 // 14 E5 // 223272
III ENSMUST00000
NM 145455 // Btfi // basic transcription factor 3 / / 13 D1 //
218490 III ENSMUST
NM 145153 // OasIf//2'-5' oligoadenylate synthetase IF //5
F|5 67.0 cM // 243
NM 144845 // Ugt3a2 // UDP glycosyltransferases 3 family,
polypeptide A2 // 15 A
NM 139147 // Rab40b // Rab40b, member RAS oncogene
family// 11 E2/ / 217371 III
NM 139138 // Emr4 // EGF-like module containing, mucin
like, hormone receptor-li
NM 134201 // Vlrf4 // vomeronasal 1 receptor, F4 / / 17 A3.2
// 171235 /// BC1254
NM 134177 // Vlrc22 // vomeronasal 1 receptor, C22 // 6 B3
// 171195 ///ENSMUST
NM 134169 // V1rc 14 // vomeronasal 1 receptor, C14 // 6 C1
/ / 171187///ENSMUST
NM 134155 // Brmsl // breast cancer metastasis-suppressor 1
/ / 19 A// 107392//
NM 134072 // Akrlcl4 // aldo-keto reductase family 1,
member C14 / / 13 A1 / / 105

Gabra5

0.002527

1.174

Apol7c

0.005312

1.441

Cdca2

0.040274

1.155

Lrrcl9

0.028637

1.212

Hbql

0.04153

-1.256

Nudtl5

0.047112

1.223

P2ryl0

0.002576

1.426

Ccdc9

0.006812

-1.178

Atf7ip2

9.78E-05

1.212

Hrh4

0.006762

1.204

Ugt2bl

0.014142

1.416

Rassf9

0.046575

1.286

Oitl

0.034439

1.185

Itgbll

0.001836

1.190

Btfi

0.030706

1.155

Oas If

0.027675

1.187

Ugt3a2

0.034321

1.190

Rab40b

0.046863

-1.156

Emr4

0.01242

1.196

Vlrf4

0.026073

1.311

Vlrc22

0.049725

1.296

Vlrcl4

0.021802

1.595

Brmsl

0.008055

-1.171

0.03421

1.228

Akrlcl4
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NM 080728 // Myh7 // myosin, heavy polypeptide 7, cardiac
muscle, beta / / 14 C3|
Myh7
NM 054066 // Plczl // phospholipase C, zeta 1 // 6 G1 //
114875 III ENSMUST00000
Plczl
NM 032006 // Mmpla // matrix metallopeptidase la
(interstitial collagénase) // 9
Mmpla
NM 031202 // Tyrpl // tyrosinase-related protein 1 // 4 C3|4
38.0 cM //22178//
Tyrpl
NM 031195 // Msrl // macrophage scavenger receptor 1 // 8
A4 8 20.0 cM // 20288
Msrl
NM 031159// Apobecl // apolipoprotein B mRNA editing
enzyme, catalytic polypept
Apobecl
NM 030735 // Vlrd9 // vomeronasal 1 receptor, D9 // 7 A3 //
81010///NM 207548
Vlrd9
NM 029961 // Abcb5 // ATP-binding cassette, sub-family B
(MDR/TAP), member 5 //
Abcb5
NM 029848 // Hyal4 // hyaluronoglucosaminidase 4 // 6 A3 //
77042 III ENSMUST000
Hyal4
NM 029726 // Trdn // triadin // 10 A4 // 76757
Trdn
NM 028561 // Speer4b // spermatogenesis associated
glutamate (E)-rich protein 4b
Speer4b
NM 028193 // Brfl // BRF1 homolog, subunit of RNA
polymerase III transcription i
Brfl
NM 028083 // Chaflb // chromatin assembly factor 1, subunit
B (p60) // 16 C4| 16
Chaflb
NM 027941 // Lrrc34 // leucine rich repeat containing 34 // 3
A3 // 71827 III EN
Lrrc34
NM 027677 // Gpr39 // G protein-coupled receptor 39 / / 1 E3
// 71111 ///NM 1451
Gpr39
NM 027206 // Tnfaip812 // tumor necrosis factor, alphaTnfaip81
induced protein 8-like 2
2
NM 027163 // Il 1f8 // interleukin 1 family, member 8 // 2
A3|2 10.3 cM //69677
IllfB
NM 026898 // Wdr53 // WD repeat domain 53 / / 16 B2 //
68980 III ENSMUST000000234
Wdr53
NM 026668 // Lrriq4 // leucine-rich repeats and IQ motif
containing 4 // 3 A3 //
Lrriq4
NM 026656 // Mcoln2 // mucolipin 2 // 3 H2 // 68279 III
NM 001005846 / / Mcoln2 /
Mcoln2
NM 025684 // Nepn // nephrocan / / 10 B3 // 66650 III
ENSMUST00000067085 // Nepn
Nepn
NM 025350 // Cpal // carboxypeptidase Al // 6 6.6 cM //
109697 III ENSMUST000000
Cpal
NM 024495 // Car 13 // carbonic anhydrase 13 // 3 A2 //
71934 III ENSMUST00000029
Carl 3
NM 024204 // Ankrd22 // ankyrin repeat domain 22 // 19
Cl|19 24.0 cM //52024//
Ankrd22

0.04812

1.204

0.004254

1.345

0.042911

1.364

0.002711

1.154

0.010879

1.307

0.041939

1.120

0.015896

1.285

0.000264

1.273

0.019234

1.211

0.018201

1.449

0.01595

1.170

0.047315

1.226

0.002294

1.157

0.02419

1.158

0.029818

1.445

0.047913

1.146

0.044847

1.338

0.019424

-1.225

0.02091

1.148

0.016921

1.265

0.048796

1.356

0.012043

1.163

0.012272

1.294

0.022416

1.294
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NM 022983 // Lpar3 // lysophosphatidic acid receptor 3 // 3
H2|3 70.5 cM // 6508
NM 022016 // Impgl // interphotoreceptor matrix
proteoglycan 1 // 9 El|9 42.5 cM
NM 021886/ / Cenph/ / centromere protein H// 13 Dl|13 51.0
cM // 26886 III ENSM
NM 021562 // Tas2rl40 // taste receptor, type 2, member 140
/ / 6G1|6 63.6 cM//
NM 021476 // Cysltrl // cysteinyl leukotriene receptor 1 // X
D // 58861 III ENS
NM 021419 // Rnf8 // ring finger protein 8 // 17 A3.3 // 58230
III BC021778 // R
NM 020574 // Kcne3 II potassium voltage-gated channel, Iskrelated subfamily, ge
NM_019651 II Ptpn9 // protein tyrosine phosphatase, non
receptor type 9 II — /
NM 019481 II Slcl3al // solute carrier family 13
(sodium/sulfate symporters), me
NM 019417 // Pdlim4 II PDZ and LIM domain 4 / / 11
B 1.3|11 28.5 cM/ / 30794///E
NM_016910// Ppm 1d // protein phosphatase 1D magnesiumdependent, delta isoform
NM 016804 // Mtx2 // metaxin 2 // 2 D // 53375 III
ENSMUST00000028511 // Mtx2 //
NM 016771 // Sultldl II sulfotransferase family ID, member
1//5 E l / / 53315//
NM_013900 // Mfi2 II antigen p97 (melanoma associated)
identified by monoclonal
NM 013887 // Opn4 // opsin 4 (melanopsin) // 14 B // 30044
///NM 001128599 //O
NM 013519 // Foxc2 // forkheadbox C2 // 8 El|8 65.5 cM //
14234 /// ENSMUST0000
NM 011996 // Adh4 // alcohol dehydrogenase 4 (class II), pi
polypeptide // 3 H2
NM 011860 // Nlrp5 // NLR family, pyrin domain containing
5 111 A2|7 2.5 cM //
NM 011784 // Aplnr // apelin receptor // 2 El // 23796 III
ENSMUST00000057019 //
NM 011541 // Tceal // transcription elongation factor A (SII)
1//1 A1//21399
NM 011410 // Slfn4 // schlafen 4 / / 11 C // 20558 III
ENSMUST00000000208 // Slfn
NM_011387 // SlclOal // solute carrier family 10 (sodium/bile
acid cotransporter
NM 011260 // Reg3g // regenerating islet-derived 3 gamma //
6 C3 // 19695 III EN
NM 010847 // Mxil // Max interacting protein 1 / / 19 D| 19
49.5 CM // 17859///N

Lpar3

0.007136

-1.176

Impgl

0.019194

1.267

Cenph

0.030048

1.209

Tas2rl40

0.024889

1.449

0.01891

1.148

Rnf8

0.008722

-1.145

Kcne3

0.003887

1.391

Ptpn9

0.003158

1.288

Slcl3al

0.031036

1.299

Pdlim4

0.043536

1.155

Ppm Id

0.020314

1.191

Mtx2

0.036933

-1.168

Sultldl

0.046945

1.299

Mfi2

0.019597

1.261

Opn4

0.034099

1.192

Foxc2

0.021329

1.183

Adh4

0.043598

1.174

Nlrp5

0.033775

1.297

Aplnr

0.049541

-1.148

Tceal

0.0409

-1.235

Slfn4

0.032953

1.164

SlclOal

0.039304

1.249

Reg3g

0.03561

1.375

Mxil

0.040729

1.196

Cysltrl
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NM_010800 // Bhlhal5 // basic helix-loop-helix family,
member a 15 // 5 G2-G3 //
NM 010782 // Mcpt9 // mast cell protease 9 / / 14 C3| 14 20.0
cM// 17232///NM 0
NM 010643 // Klklb24 // kallikrein 1-related peptidase b24 //
7 B4|7 23.04 cM //
NM 010430 // Hicl // hypermethylated in cancer 1 / / 11
B5| 11 47.65 cM// 15248/
NM 009411 // Tpbpa // trophoblast specific protein alpha //
13 B2|13 36.0 cM//
NM 009244 // Serpinalb // serine (or cysteine) preptidase
inhibitor, clade A, me
NM 009243 // Serpinal a // serine (or cysteine) peptidase
inhibitor, clade A, mem
NM 009140 // Cxcl2 // chemokine (C-X-C motif) ligand 2 // 5
El 5 51.0 cM // 2031
NM 009020 // Rag2 // recombination activating gene 2 // 2
E2|2 56.0 cM// 19374
NM 008887 // Phox2a // paired-like homeobox 2a // 7 E3|7
50.0 cM // 11859 III EN
NM 008674 // Nat3 // N-acetyltransferase 3 // 8 B3.3 8 31.0
cM // 17962 III ENSM
NM 008644 // Proll // proline rich, lacrimal 1 // 5 El // 17830
III ENSMUST00000
NM 008463 // Klra5 // killer cell lectin-like receptor,
subfamily A, member 5 //
NM 008329 // Ifi204 // interferon activated gene 204 // 1 H3|l
95.2 cM// 15951
NM 008223 // Serpindl // serine (or cysteine) peptidase
inhibitor, clade D, memb
NM 008152 // Gpr65 // G-protein coupled receptor 65 / / 12 E
// 14744 III ENSMUST
NM 008009 // Fgfbpl // fibroblast growth factor binding
protein 1 // 5 B3 // 141
NM 008004 // Fgfl7 // fibroblast growth factor 17 // 14 D2|14
38.0 cM //14171/
NM 007946 // Epx // eosinophil peroxidase / / 11 C 11 49.0
cM// 13861 ///ENSMUS
NM 007887 // Dubl // deubiquitinating enzyme 1 // 7 E3|7
51.5 cM// 13531 ///NM
NM 007786 // Csn3 // casein kappa // 5 El|5 45.2 cM // 12994
III ENSMUST00000001
NM 007705 // Cirbp // cold inducible RNA binding protein //
10 C l110 44.0 cM //
NM 007684 // Cetn3 // centrin 3 / / 13 C3 // 12626 III
ENSMUST00000022009 // Cetn
NM 007659 // Cdc2a // cell division cycle 2 homolog A (S.
pombe)// 10 B5.3I10 3

Bhlhal5

0.000801

1.186

Mcpt9

0.036189

1.235

Klklb24

0.048887

1.272

Hicl

0.022121

1.162

Tpbpa
Serpinal
b
Serpinal
a

0.020972

1.362

0.029932

1.724

0.038424

1.238

Cxcl2

0.046183

-1.156

Rag2

0.010639

1.296

Phox2a

0.003887

1.381

Nat3

0.0058

1.272

Proll

0.005612

1.178

Klra5

0.027148

1.410

Ifi204

0.04021

1.229

Serpindl

0.041532

1.235

Gpr65

0.038372

1.245

Fgfbpl

0.002469

1.220

Fgfl7

0.035849

-1.176

Epx

0.015122

-1.149

Dubl

0.042273

1.145

Csn3

0.020312

1.217

Cirbp

0.018836

-1.202

Cetn3

0.034823

-1.151

Cdc2a

0.044333

1.187
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NM OOl 162865 // Cylc2 // cylicin, basic protein of sperm
head cytoskeleton 2 //
NM 001099301 // Lcnl4 // lipocalin 14 // 2 A3 // 383678 III
ENSMUST00000114192/
NMOO1042605 // Cd74 // CD74 antigen (invariant
polypeptide of major histocompat
NM 001042421 // Kntcl // kinetochore associated 1 // 5 F //
208628 III ENSMUST00
NM 001039554 // Angptl7 // angiopoietin-like 7 // 4 El //
654812 III ENSMUST0000
NM 001037822 // Krtap5-5 // keratin associated protein 5-5 //
7 F5 // 114666 III
NM 001033361 // Pgr 151 // G protein-coupled receptor 15like // X C3 // 245526 /
NM 001033290 // Gpr55 // G protein-coupled receptor 55 // 1
C5 // 227326 III ENS
NM 001033240 // Wfdc6a // WAP four-disulfide core domain
6A/ / 2 H 3//209351 //
NM 001029868 // Pdzd4 // PDZ domain containing 4 // X
A7.3 // 245469 III ENSMUST
NM 001024848 // Apol7b // apolipoprotein L 7b / / 15 El //
278679///NM 00113480
NM 001024720 // Hmcnl // hemicentin 1 / / 1 G1 // 545370 III
ENSMUST00000074783 /
NM 001024714 // Cma2 // chymase 2, mast cell / / 14 C3 //
545055///NM 010782//
NM 001013765 // Zscan4c // zinc finger and SCAN domain
containing 4C // 7 A1 //
NM 001013609 // Tex24 // testis expressed gene 24 // 8 A2 //
541463 III ENSMUST0
NM 001008549 // Zfp658 // zinc finger protein 658 // 7 B4 //
210104///ENSMUST0
NM 001003405 // Try5 // trypsin 5 // 6 B1 // 103964 III
AB009661 // Try5 // tiyp
NM 001002898 // Sirpbl // signal-regulatory protein beta 1 //
3 A1 // 320832 III
NM 001001130 // Zfp85-rsl // zinc finger protein 85, related
sequence 1 / / 13 B3
FJ889356 // Nlrc5 // NLR family, CARD domain containing 5
// 8 C5 // 434341
ENSMUST00000104947 // Capns2 // calpain, small subunit 2
// 8 C5 // 69543
ENSMUST00000103234 // Fbnl // fibrillin 1 // 2 F|2 71.0 cM
// 14118 III ENSMUST0
ENSMUST00000099638 // Dcdc5 // doublecortin domain
containing 5 // 2 E3 // 32948
ENSMUST00000094237 // AdamtsB // ADAMTS-like 3 // 7
D3 // 269959 III AK220376 /

Cylc2

0.008672

1.365

Lcnl4

0.007374

1.179

Cd74

0.043104

1.159

Kntcl

0.030857

1.191

Angptl7

0.001036

1.409

Krtap5-5

0.047794

1.294

Pgrl51

0.005097

1.174

Gpr55

0.007436

1.208

Wfdc6a

0.012886

1.264

0.0427

-1.191

Apol7b

0.015399

1.218

Hmcnl

0.032575

1.207

Cma2

0.036575

1.248

Zscan4c

0.044902

1.342

Tex24

0.04818

1.292

Zfp658

0.017052

1.219

Try5

0.034659

1.191

Sirpbl
Zfp85rsl

0.040764

1.157

0.006928

1.197

Nlrc5

0.037688

1.182

Capns2

0.041642

-1.550

Fbnl

0.002559

1.188

Dcdc5
Adamtsl
3

0.006694

1.291

0.047137

1.199

Pdzd4
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0.02183

1.335

Zfp558

0.011846

1.351

Nup2101

0.003267

1.358

0.018089

-1.310

0.008697

-1.184

CTQ

O

Zfp229

o

ENSMUST00000065871 // Zfp229 // zinc finger protein // 17
A3.3// 381067 ///BCO
ENSMUST00000034647 // Zf]p558 // zinc finger protein 558 //
9 A3 // 72230
ENSMUST00000029548 // Nup2101 // nucleoporin 210-like //
3 F2 // 77595
BC056454 // Crygc // crystallin, gamma C / / 1 C2|l 32.0 cM //
12966
BC013522 // Cisdl // CDGSH iron sulfur domain 1 / / 10
B5.3I10 38.0 cM 7/52637/

Cisdl
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Appendix E

GeneAssignment
NM 009574 // Zic2 // zinc finger protein of the cerebellum 2
// 14 E5| 14 62.0 cM
NM 026250 // Zh2c2 // zinc finger, H2C2 domain containing
//I D // 252876 III E
NM 001081065 // Zfp707 // zinc finger protein 707 // 15 D3 //
69020 III ENSMUST0
NM 009329 // Zfp354a // zinc finger protein 354A / / 11
B1.3| 11 28.0 cM //21408
NM 013889 // Zfp292 // zinc finger protein 292 // 4 A5 4 17.2
cM // 30046 III EN
NM 011705 // Vrkl // vaccinia related kinase 1 / / 12 FI //
22367///NM 00102984
NM 001105057 // Vmn2r60 // vomeronasal 2, receptor 60 // 7
B3|7 // 637898 III EN
NM 134203 // Vlrg2 // vomeronasal 1 receptor, G2 // 7 A1 //
171237///ENSMUST00
NM 134179 // Vlrc24 // vomeronasal 1 receptor, C24 // 6 B3
// 171197/// ENSMUST
NM 053227 // Vlrb4 // vomeronasal 1 receptor, B4 // 6 D1 //
113854///ENSMUST00
NM 144937 // Usp3 // ubiquitin specific peptidase 3 // 9 C //
235441 ///ENSMUST
NM 011667 // Ubelyl // ubiquitin-activating enzyme El, Chr
Y 1 // Y A1 / / 22202
NM 019551 // Ttrap // TRAF and TNF receptor associated
protein//13 A3.1113 12.
NM 011623 // Top2a // topoisomerase (DNA) II alpha // 11
D|ll 57.0 cM //21973/
NM 145561 // Tmprssl Id // transmembrane protease, serine
l i d / / 5 E l/ / 231382/
NM 009390 // Till // tolloid-like // 8 B3.1|8 32.4 cM // 21892
III ENSMUST000000
NM 009359 // Tex9 // testis expressed gene 9 // 9 D // 21778
III ENSMUST00000085
NM 013774 // Tcllb4 // T-cell leukemia/lymphoma IB, 4 //
12 E // 27380 III ENSMU
NM 199059 // Tbpl2 // TATA box binding protein like 2 // 2
A3 // 227606 III ENSM
NM 020501 // Tas2rl05 // taste receptor, type 2, member 105
// 6 F3|6 62.0 cM //
NM_177342 // Taf5 // TAF5 RNA polymerase II, TATA box
binding protein (TBP^-asso
BC085089 // Styx // serine/threonine/tyrosine interaction
protein / / 14 Cl // 56

Gene
Symbol
Zic2
Zh2c2
Zfp707
Zfp354a
Zfp292
Vrkl
Vmn2r6
0
Vlrg2
Vlrc24
Vlrb4
Usp3
Ubelyl
Ttrap
Top2a
Tmprssl
Id
Till
Tex9
Tcllb4
Tbpl2
Tas2rl05
Taf5
Styx

Foldp-value
change
0.040045
6
-1.326
0.029729
0.024175
5
0.021929
3
0.033415
1
0.004312
8
0.026861
6
0.018356
5
0.037904
3

-1.177

0.04635
0.045328
4
0.031772
3
0.001374
5
0.016618
3
0.004203
9
0.025026
6
0.037818
5
0.035364
3
0.012968
9
0.034144
6
0.039201
5
0.022359
5

1.244

-1.187
-1.198
-1.183
-1.170
1.156
1.219
1.761

-1.241
-1.407
-1.187
1.516
-1.181
-1.204
-1.157
-1.169
1.211
1.168
-1.169
-1.450
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NM 199319 // Ssxb5 // synovial sarcoma, X member B,
breakpoint 5 //XA1.1|X// 3
NM 009263 // Sppl // secreted phosphoprotein 1 // 5 E5|5
56.0 cM // 20750 III EN
NM 028561 // Speer4b // spermatogenesis associated
glutamate (E)-rich protein 4b
NM 001146013 // Slc6a5 II solute carrier family 6
(neurotransmitter transporter,
NM 001001321 // Slc35d2 // solute carrier family 35, member
D2 // 13 B3 // 70484
NM_172371 // Sic 16a 13 // solute carrier family 16
(monocarboxylic acid transport
NM 172838 // Slcl6al2 // solute carrier family 16
(monocarboxylic acid transport
NM 009194 // Slcl2a2 // solute carrier family 12, member 2 //
18 D3| 18 32.0 cM /
NM 001079695 // Sfrs5 // splicing factor, arginine/serine-rich
5 (SRp40, HRS) //
NM 025669 // Sirs 18 // splicing factor, arginine/serine-rich 18
// 4 A3 // 66625
AF357342 // Scamal7 // small Cajal body-specific RNA 17 //
18| 18 // 100217466
AF357342 // Scamal7 // small Cajal body-specific RNA 17 //
18 18// 100217466
NM 001013769 // Rsll // regulator of sex limited protein 1 //
13 B3| 13 40.0cM/
XM 915909 // Rgs21 // regulator of G-protein signalling 21 //
1 F / / 624910
NM 139292 // Reep6 // receptor accessory protein 6 / / 10 Cl
// 70335 III ENSMUST
NM 016809 // Rbm3 // RNA binding motif protein 3 // X
A1.1|X 2.0 cM // 19652///
NM 016809 // Rbm3 // RNA binding motif protein 3 // X
A 1.1 |X 2.0 cM // 19652 III
NM 001045807 // Rbml5 // RNA binding motif protein 15 //
3 F2.3 // 229700 III EN
NM 008979 // Ptpn22 // protein tyrosine phosphatase, non
receptor type 22 (lymph
NM 008644 // Proll // proline rich, lacrimal 1 // 5 El // 17830
III ENSMUST00000
NM 011164// Prl // prolactin / / 13 A3.1113 14.0 cM/ / 19109
III ENSMUST00000018
NM 001033281 // Prdm6 // PR domain containing 6 / / 18 D1
/ / 225518///ENSMUST00
NM 172146 // Ppat // phosphoribosyl pyrophosphate
amidotransferase // 5 C3.3 //
NM 008849 // Poulfl // POU domain, class 1, transcription
factor 1 (Pit 1, growth

Ssxb5
Sppl
Speer4b
Slc6a5
Slc35d2
Slcl6al3
Slcl6al2
Slcl2a2
Sffs5
Sfrsl 8
Scarna17
Scarna 17
Rsll
Rgs21
Reep6
Rbm3
Rbm3
Rbml5
Ptpn22
Proll
Prl
Prdm6
Ppat
Poulfl

0.030056
7
0.025213
5
0.008560
9
0.025722
4
0.041046
1
0.043664
6
0.035537
9
0.043069
4
0.024360
5
0.044271
2
0.033860
1
0.033860
1
0.019415
0.029720
7
0.022389
2
0.001902
5
0.001378
1
0.017955
3
0.001086
1
0.006202
0
0.014800
7
0.042364
5
0.019249
4
0.043443
4

1.840
-1.351
1.179
-1.645
1.160
-1.160
-1.150
-1.171
-1.176
-1.171
-1.179
-1.179
-1.281
1.194
-1.175
-1.259
-1.251
-1.156
-1.272
1.166
15.616
1.173
-1.153
1.278
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NM 175170// Pogk // pogo transposable element with K.RAB
domain / / 1 H2.3 // 715
NM 011495 // Plk4 // polo-like kinase 4 (Drosophila) // 3 B //
20873 III ENSMUST
NM 178939 // Pdrgl // p53 and DNA damage regulated 1 // 2
HI // 68559 III ENSMUS
NM 029620 // Pcolce2 // procollagen C-endopeptidase
enhancer 2 // 9 E3.3 // 7647
NM 053143 // Pcdhb 18 // protocadherin beta 18 / / 18 B3 //
93889 III ENSMUST00000
NM 053141 // Pcdhb 16 // protocadherin beta 16 // 18 B3 //
93887 III ENSMUST00000
NM 013627 // Pax6 // paired box gene 6 // 2 E3 2 58.0 cM //
18508 III ENSMUST000
NM 181753 // Opn5 // opsin 5 / / 17 B3 // 353344 III
ENSMUST000000683 55 // Opn5 /
NM 146865 // 01fr992 // olfactory receptor 992 //
258865 III ENSMUST00000
NM 146749 // 01fr875 // olfactory receptor 875 //
258744 III ENSMUST00000
NM 207159 // 01ff814 // olfactory receptor 814 / / 10 D3 //
259165 III ENSMUST000
NM 146813 // Olff651 // olfactory receptor 651 II 258809 III ENSMUST00000
NM 147041 // 01ff57 // olfactory receptor 57 // 10 Cl //
18357 III ENSMUST000000
NM 146922 // 01fr376 // olfactory receptor 376 // — //
258924///NM 146923//
NM 207567 // Olfrl 198 // olfactory receptor 1198 // 2 El //
404330 III ENSMUST00
NM 013724 // Nrk // Nik related kinase // X F1|X 53.0 cM //
27206 III ENSMUST000
NM 001082476 // Ndorl // NADPH dependent diflavin
oxidoreductase 1 // 2 A3 // 78
NM 001162417 // Myef2 // myelin basic protein expression
factor 2, repressor //
NM 008651 // Mybll // myeloblastosis oncogene-like 1 // 1
A2|l 3.0 cM// 17864/
NM 001146180 // Mtssl // metastasis suppressor 1 / / 15 D1 //
211401///NM 14480
NM 181409 // Mtmrl 1 // myotubularin related protein 11 // 3
F2.1 // 194126///E
NM 144898 // Mstol // misato homolog 1 (Drosophila) // 3
FI // 229524 III ENSMUS
ENSMUST00000067600 // Ms4al4 // membrane-spanning 4domains, subfamily A, member
NM_ 198224 // Ms4al3 // membrane-spanning 4-domains,
subfamily A, member 13 / / 19

Pogk
Plk4
Pdrgl
Pcolce2
Pcdhb18
Pcdhb16
Pax6
Opn5
01fr992
01ff875
Olfi-814
01ff651
01ff57
01ff376
Olfrl 198
Nrk
Ndorl
Myef2
Mybll
Mtssl
Mtmrl 1
Mstol
Ms4al4
Ms4al3

0.037319
3
0.036132
5
0.049710
9

-1.190
-1.185
-1.165

0.047399
0.019106
3
0.042402
2
0.030123
8

-1.167

0.010073
0.001960
5
0.006256
2
0.040755
7
0.035912
9
0.045330
7

1.230

0.022866
0.030295
7
0.027241
2
0.013851
2
0.034323
9
0.031843
8
0.030710
8
0.007247
7
0.048102
5
0.033805
3
0.028165
7

-1.186
-1.179
-1.283

-1.187
1.161
1.172
1.223
1.244
1.246
1.331
-1.194
-1.168
-1.227
-1.211
-1.252
-1.160
-1.120
1.179
1.417
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NM 177719 // Morc2b // microrchidia 2B / / 17 B1 // 240069
III ENSMUST00000053896
NM 008611 // Mmp8 // matrix metallopeptidase 8 // 9 A1 II
17394 III ENSMUST00000
NM 010789 // Meisl // Meis homeobox 1 / / 11 A3.1111 11.0
cM // 17268 III ENSMUST
NM 001001979 // MegflO // multiple EGF-like-domains 10 //
18 D 3//70417///ENS
NM 008568 // Mcm7 // minichromosome maintenance
deficient 7 (S. cerevisiae) // 5
NM 013871 / / Mapk 12//mitogen-activated protein kinase 12
// 15 E3 // 29857 III
NM 138680 // Luc712 // LUC7-like 2 (S. cerevisiae) // 6 B1 //
192196///ENSMUST
NM 008501 // Lif // leukemia inhibitory factor // 11 Al-A2|l 1
0.25 cM// 16878/
NM 001018079 // Lce3f // late comified envelope 3F // 3 FI //
69520 III ENSMUST
ENSMUST00000103366 // LOC100046973 // similar to
[Human Ig rearranged gamma chai
BC147119 // L3mbtl4 // l(3)mbt-like 4 (Drosophila) / / 17 E1.2
/ / 320858///NM 1
NM 001037822 // Krtap5-5 // keratin associated protein 5-5 //
7 F5 // 114666 III
NR 003957 // Krt36 // keratin 36 / / 11 D // 16673 III
ENSMUST00000107416 // Krt3
NM 033373 // Krt23 // keratin 23 / / 11 D // 94179 III
ENSMUST00000006969 // Krt2
NM 011177// Klk6 // kallikrein related-peptidase 6 // 7 B4B5|7 24.0 cM // 1914
NM 172781 // Klhl4 // kelch-like 4 (Drosophila) // X El //
237010 ///ENSMUST000
NM 010608 // Kcnk3 // potassium channel, subfamily K,
member 3 // 5 B|5 18.0 cM
NM 029911 // KcnklO // potassium channel, subfamily K,
member 10//12 E // 7225
NM 001110227 // Kcnj 13 // potassium inwardly-rectifying
channel, subfamily J, me
NM 173441 // Iwsl // IWS1 homolog (S. cerevisiae) // 18 B3
// 73473 III ENSMUST0
NM 008389 // Ipp // IAP promoted placental gene // 4 D114
51.4 cM// 16351 /// E
NM 054079 // Iltifb // interleukin 10-related T cell-derived
inducible factor be
NM 175115// Ikzf5 // IKAROS family zinc finger 5 // 7 F3 //
67143///ENSMUST00
NM 153087 // Hrh4 // histamine receptor H4 / / 18 A1 //
225192 III ENSMUST0000004

Morc2b
Mmp8
Meisl
MegflO
Mcm7
Mapk 12
Luc712
Lif
Lce3f
LOCI 00
046973
L3mbtl4
Krtap5-5
Krt36
Krt23
Klk6
Klhl4
Kcnk3
KcnklO
Kcnj 13
Iwsl
Ipp
Iltifb
Ikzf5
Hrh4

0.047678
8
0.039153
3
0.007413
8
0.045611
3
0.017361
1
0.007431
1
0.030652
4
0.038887
2
0.018015
0.011965
2
0.020018
8
0.032634
5
0.014629
7
0.035341
2
0.022020
9
0.012111
6
0.044182
4
0.046429
9
0.038984
1
0.044062
6
0.035868
8
0.001120
8
0.005831
5
0.025184
6

-1.232
1.239
-1.303
-1.184
-1.180
-1.247
-1.179
1.162
-1.208
1.431
1.226
1.344
1.159
1.162
-1.237
-1.267
-1.146
-1.276
-1.231
-1.187
-1.169
-1.634
-1.156
1.146
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NM 010452 // Hoxa3 // homeo box A3 // 6 B3 6 26.3 cM //
15400 III ENSMUST0000011
NM 175606 // Hopx // HOP homeobox // 5 C3.3 // 74318 III
NM 001159900//Hopx//
NM 001146153 // Homer3 // homer homolog 3 (Drosophila)
// 8 Cl // 26558 III NM 0
NM 029804 // Hnmpm // heterogeneous nuclear
ribonucleoprotein M // 17 B1 // 769
BC113153// Gsdmc2 // gasdermin C2/ / 15 D1 / / 331063
NM 010350 // Grin2c // glutamate receptor, ionotropic,
NMDA2C (epsilon 3) / / 11
NM 001033290 // Gpr55 // G protein-coupled receptor 55 / / 1
C5 // 227326 III ENS
NM 010326 // Gplba // glycoprotein lb, alpha polypeptide //
11 B4|l 1 42.0 cM //
NM 001033275 // Glt8d3 // glycosyltransferase 8 domain
containing 3 / / 15 E3 //
NM 020492 // Glral // glycine receptor, alpha 1 subunit / / 11
B1.3|l 1 30.0 cM//
NM 010294 // Gk2 // glycerol kinase 2 // 5 E3|5 53.0 cM //
14626 III ENSMUST0000
NM 008117 // Gh // growth hormone // 11 D| 11 65.0 cM //
14599 III ENSMUST0000010
NM_173030 // Galntl3 // UDP-N-acetyl-alpha-Dgalactosamine:polypeptide N-acetylg
NM 001099641 // Gabra6 // gamma-aminobutyric acid
(GABA) A receptor, subunit alp
NM 010242 // Fut4 // fucosyltransferase 4 // 9 A2|9 3.0 cM //
14345 III ENSMUST0
NM 008045 // Fshb // follicle stimulating hormone beta // 2
E3|2 60.0 cM / / 1430
NM 180974 // Foxn2 // forkhead box N2 // 17 E5 // 14236 III
ENSMUST00000112238 /
NM 013519 // Foxc2 // forkhead box C2 // 8 El|8 65.5 cM //
14234 III ENSMUST0000
NM 001033244 // Fancd2 // Fanconi anemia,
complementation group D2 // 6 E3 // 21
BC 147234 // Fam92b // family with sequence similarity 92,
member B //8 El // 43
NM 144886 // Exosc2 // exosome component 21/2 B II
227715 III ENSMUST0000003 84
NM 198303 // Eif5b // eukaryotic translation initiation factor
5B // 1 B // 2269
NM 010100 // Edar // ectodysplasin-A receptor / / 10 B3| 10
29.0 cM// 13608 ///E
NM 007900 // Ect2 // ect2 oncogene // 3 B // 13605 III
ENSMUST00000108298 // Ect

Hoxa3
Hopx
Homer3
Hnmpm
Gsdmc2
Grin2c
Gpr55
Gplba
Glt8d3
Glral
Gk2
Gh
Galntl3
Gabra6
Fut4
Fshb
Foxn2
Foxc2
Fancd2
Fam92b
Exosc2
Eif5b
Edar
Ect2

0.011290
7
0.011828
2
0.039814
6
0.034845
4
0.041424
9
0.031969
7
0.008600
0
0.027546
7
0.020207
6
0.046105
8
0.043981
7
0.006102
5
0.033504
9
0.013286
3
0.022070
4
0.006698
6
0.017312
7
0.045165
2
0.026129
1
0.032438
6
0.046638
4
0.034835
8
0.020761
3
0.013065
1

1.173
-1.227
-1.183
-1.156
1.408
-1.240
1.171
-1.154
-1.218
-1.434
1.157
20.40
-1.240
-1.431
-1.164
1.266
-1.158
-1.150
1.155
1.186
-1.151
-1.145
1.176
-1.176
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NM 001013368 // E2f8 // E2F transcription factor 8 // 7 B4 //
108961 ///ENSMUST
NM 178609 // E2f7 // E2F transcription factor 7 / / 10 Dl|10
59.0 cM // 52679 III
NM 001033344 II Dusp27 // dual specificity phosphatase 27
(putative) Il 1 H2.3 /
NM 001001559 II Dub2a II deubiquitinating enzyme 2a II 1
E3 // 384701 III ENSMUS
NM 021317 // Dnajb7 II DnaJ (Hsp40) homolog, subfamily
B, member 7 / / 15 El // 5
ENSMUST00000064948 II Dnahc6 // dynein, axonemal,
heavy chain 6 // 6 Cl [6 31.0 c
XM 355934 II Dnahc3 // dynein, axonemal, heavy chain 3 // 7
F2 // 381917
XM 355934 II Dnahc3 // dynein, axonemal, heavy chain 3 // 7
F2 // 381917
NM 177564 // Dhrsl 1 // dehydrogenase/reductase (SDR
family) member 11 // 11 C //
NM 139222 // Defbl5 // defensin beta 15 // 8 A4 // 246082 III
ENSMUST00000062586
NM 010018 // Dao // D-amino acid oxidase // 5 F|5 65.0 cM II
13142///ENSMUST00
NM 173436 II Cypt2 II cysteine-rich perinuclear theca 2 // X
D // 245566 III ENS
NM_007817 // Cyp2f2 // cytochrome P450, family 2,
subfamily f, polypeptide 2 II
NM 007811 // Cyp26al // cytochrome P450, family 26,
subfamily a, polypeptide 1 /
NM 021351 // Cryba4 // crystallin, beta A4 // 5 F // 12959 H,
ENSMUST0000011238
NM 145151 // Crebzf // CREB/ATF bZIP transcription factor
// 7 El // 233490 III
NM 175651 // Cnpyl // canopy 1 homolog (zebrafish) // 5 B1
// 269637 III ENSMUST
NM 019948 // Clec4e // C-type lectin domain family 4,
member e // 6 F3|6 59.6 cM
NM 007705 // Cirbp // cold inducible RNA binding protein //
10 C111044.0cM//
NM 023543 // Chn2 // chimerin (chimaerin) 2 // 6 B3 // 69993
/// ENSMUST00000067
NM 001081417 // Chd7 // chromodomain helicase DNA
binding protein 7 // 4 Al 14 1.
NM 007593 // Cetnl // centrin 1 // 18 A2 // 26369 ///
ENSMUST00000062769 // Cetn
NM 028959 // Cep72 // centrosomal protein 72 // 13 Cl //
74470 /// ENSMUST000000
NM 175315 // Ceacaml5 // carcinoembryonic antigen-related
cell adhesion molecule

E2f8
E2f7
Dusp27
Dub2a
Dnajb7
Dnahcô
Dnahc3
Dnahc3
Dhrsl 1
Defbl5
Dao
Cypt2
Cyp2f2
Cyp26al
Cryba4
Crebzf
Cnpyl
Clec4e
Cirbp
Chn2
Chd7
Cetnl
Cep72
Ceacaml
5

0.037396
7
0.006558
4
0.014080
4
0.031987
5
0.023017
9
0.043642
2
0.016351
9
0.034099
8
0.045673
2
0.027719
5
0.010172
3
0.020125
7
0.040679
2
0.023524
1
0.007489
5
0.004783
8
0.005995
7
0.033123
2
0.029468
9
0.030846
3
0.011973
0.049643
1
0.026124
9
0.043110
2

-1.198
1.175
1.171
1.347
1.205
1.154
1.218
-1.201
-1.226
1.148
-1.279
-1.176
1.247
-1.481
1.182
-1.221
-1.342
1.185
-1.240
-1.213
-1.380
-1.146
-1.167
1.185
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NM 146040 // Cdca71 // cell division cycle associated 7 like //
12 F2 // 217946
NM 009860 // Cdc25c // cell division cycle 25 homolog C (S.
pombe)// 18 B1118 1
NM 172587 // Cdcl4b // CDC14 cell division cycle 14
homolog B (S. cerevisiae) //
NM 207244 // Cd200r4 // CD200 receptor 4 / / 16 B4 //
239849 III AY230200 // Cd20
NM 019820 // Cbln3 // cerebellin 3 precursor protein // 14
C3 14 22.5 cM // 5641
NM 019626 // Cblnl // cerebellin 1 precursor protein // 8 C3|8
40.0 cM // 12404
NM 009807 // Caspl // caspase 1 // 9 Al|9 1.0 cM // 12362 III
BC008152 // Caspl
NM 007592 // Car8 // carbonic anhydrase 8 // 4 Al|4 7.7 cM
// 12319 III BC010773
NM 001013767 // Capnl 1 // calpain 11 // 17 B3 // 268958 III
ENSMUST00000120717 /
NM 023341 // Cabcl // chaperone, ABC1 activity of bcl
complex like (S. pombe) //
NM 178640 // B3galnt2 // UDP-GalNAc:betaGlcNAc beta
1,3-galactosaminyltransferas
NM 023066 // Asph // aspartate-beta-hydroxylase // 4 A1 //
65973///NM 133723/
NM 175391 // Apol7c // apolipoprotein L 7c // 15 El //
108956 III ENSMUST0000006
NM 001033303 // Ampdl // adenosine monophosphate
deaminase 1 (isoform M) // 3 F2
NM 028717 // Als2 // amyotrophic lateral sclerosis 2
(juvenile) homolog (human)
NM 145223 // Almsl // Alstrom syndrome 1 homolog
(human) // 6 C3 // 236266 III E
NM 028270/ / Aldhlbl / / aldehyde dehydrogenase 1 family,
member B1 //4B 2//72
NM 009647 // Ak311 // adenylate kinase 3-like 1 // 4 C6 4
47.6 cM // 11639 III B
NM 007419 // Adrbl // adrenergic receptor, beta 1 / / 19 D2| 19
51.0 cM// 11554/
NM 009605 // Adipoq // adiponectin, C1Q and collagen
domain containing / / 16 16.
NM 172619 // AdamtslO // a disintegrin-like and
metallopeptidase (reprolysin typ
NM 001025380 // Adam39 // a disintegrin and
metallopeptidase domain 39 // 8 A4 /
NM 054094 // Acsml // acyl-CoA synthetase medium-chain
family member 1 // 7 F3 /
NM 029961 // Abcb5 // ATP-binding cassette, sub-family B
(MDR/TAP), member 5 //

Cdca71
Cdc25c
Cdcl4b
Cd200r4
Cbln3
Cblnl
Caspl
Car8
Capnl1
Cabcl
B3galnt2
Asph
Apol7c
Ampdl
Als2
Almsl
Aldhlbl
Ak311
Adrbl
Adipoq
Adamtsl
0
Adam39
Acsml
Abcb5

0.005991
6
0.023950
3
0.038675
2
0.011579
9
0.011181
5
0.030637
5
0.017822
4
0.001253
4
0.000429
5
0.037003
8
0.015079
3
0.016459
3
0.016219
3
0.035014
9
0.024071
9
0.016767
9
0.036435
9
0.005953
6
0.005978
9
0.015585
6
0.031137
8
0.021610
6
0.041354
9
0.035661
4

1.222
1.249
-1.203
1.199
-1.467
-1.296
1.156
-1.321
-1.292
-1.164
-1.120
-1.168
-1.327
1.269
-1.219
-1.145
-1.157
-1.174
1.145
1.145
-1.312
1.444
1.245
1.185

